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INTRODUCTION
“Why do I have blue eyes?” A typical question related to genetics usually answered 
with: “You inherited it from your parents”. This answer is based on traditional 
genetics; ‘The study of how living things receive traits from previous generations’ 
[1]. We can study inherited traits, such as eye color, through the genetic information 
encoded by Desoxyribo Nucleic Acid (DNA). Human DNA consist of sequences of 
over six billion nucleotides, these nucleotides form Watson and Crick base pairs (bps) 
in a double helix structure. In humans, DNA is distributed over 46 chromosomes 
which form 23 chromosome pairs, collectively called the genome. 
DNA is usually studied through a process called sequencing, once the sequence of a 
genomic region is known it can be compared to the sequence of other individuals. 
When looking for an explanation for differences in a trait, for example eye color, 
a comparison step is crucial, only those regions of the genome which vary in the 
human population are informative. When comparing the genome of two individuals 
only a small portion of the genome is informative, approximately 4 million bps [2,3], 
since most of the DNA (~99.9%) is identical between any two humans. 
Genetic variation can have an effect on the physical characteristics of an individual 
such as eye color. Studying the DNA of individuals with either brown eyes or blue 
eyes for example revealed differences between the two groups in a region on 
chromosome 15 [4]. Within this region lies the OCA2 gene, a gene which encodes a 
protein involved in melanin-based pigment formation. The level at which this gene 
is expressed determines the level of this pigment in the human body, higher levels 
of pigment result in darker skin and eye color [4].
Knowledge about the region of the genome containing the OCA2 involved in eye 
color allowed researchers to study where and when the original variation occurred 
and how it spread through the population [4,5]. As a result several small mutations 
(affecting only a single base pair (bp)) have been identified in and near the OCA2 
gene which decrease the expression level in individuals with blue eyes [6,7]. Since 
the human ancestors had brown eyes [5] the mutation must have been introduced 
somewhere in our genetic history, when the first child with light brown or even 
blue eyes was born from parents with brown eyes. In this case a so-called de novo 
mutation occurred; a mutation was present in the DNA of the child which was not 
present in its parents. If a de novo mutation occurs during the formation of either 
the sperm or egg cell which is then involved in fertilization, the de novo mutation 
will be present in all cells of the child, including the germline. Those mutations 
present in the germline are important when studying inherited traits as only the 
DNA of germ cells can be transmitted to future offspring.
The example of blue eyes demonstrates how a de novo mutation occurred which 
had an effect on the phenotype and was subsequently passed on to future 
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Figure 1, Schematic overview of the different mutation types, A) Single nucleotide variant 
(SNV), B) Insertion or deletion event (InDel), C) Copy number variants (CNV), D) Aneuploidy, 
E) Inversion, F) Translocation. Italic gray text lists examples of techniques traditionally used 
to detect these types of mutations.
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generations. But what effect did it have on future generations and how did such 
a mutation occur in the first place? While one might not immediately suspect so, 
the mutations responsible for blue eyes have been subject to positive selection [4]. 
After many centuries of natural selection we can observe its outcome by studying 
the frequency of the mutation in the human population. The mutations responsible 
for blue eyes are observed most frequently in the northern parts of Europe [8]. The 
mutations seem to have had some beneficial effect only in this particular region 
of the world as they are rarely observed in populations from other regions [4]. A 
possible explanation for this effect is related to the fact that these are regions with 
less sun exposure [8]. 
Humans had to adapt as they migrated north from the sunny regions of Africa to 
the colder and relatively dark regions of northern Europe [9]. Blue eyes are a result 
of this adaptation process as lower amounts of pigmentation are associated to 
greater responsiveness to sun light [10]. A greater responsiveness to sunlight meant 
that individuals with these mutations required less sunlight to maintain important 
chemical processes such as vitamin D formation [11]. The OCA2 mutations are an 
example of how de novo mutations can result in positive selection under certain 
environmental conditions.
So how did the mutations occur in the first place? The process of mutation is a 
natural phenomenon which occurs during the replication of DNA. When a cell 
divides to make two new cells the DNA of the original cell is copied. Even though 
the copying process is highly reliably and makes only one mistake for every 100,000 
nucleotides it copies, it would accumulate to approximately 120,000 mistakes for 
our complete genome as over 6 billion bps (12 billion nucleotides) have to be copied 
[12]. However, cells also have a proof reading and error correction mechanism 
which corrects more than 99% of the errors introduced during the copying process 
[12]. DNA copying errors which are not corrected will become de novo mutations 
in a subsequent cell division cycle. The average number of mutations which occur 
through this process in the sperm and egg cells which are passed on to a new 
generation determine the so-called per generation mutation rate.
The per generation mutation rate plays an important role in human disease as was 
first described in 1935 [13]. It was hypothesized that certain human diseases can only 
be caused by de novo mutations because patients do not reach their reproductive 
age [13]. When affected individuals do not reach their reproductive age they will 
have no offspring which could inherit the mutation. For example Down syndrome, 
caused by a de novo duplication of chromosome 21, is associated with severe 
intellectual disability [14]. The additional copy of a whole chromosome has severe 
effects on the reproductive fitness of affected individuals from an early age [15]. 
A mutation with such severe effects on fitness is under strong negative selection 
13
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as it will rarely be passed on to future generations. However most mutations do 
not exert a phenotypic effect and some mutations, such as those in OCA2, may 
even be advantageous to an individual under certain conditions. But what kinds of 
mutations are exactly present and how are these detected when studying genetic 
diseases?
IN SEARCH OF MUTATIONS CAUSING DISEASE
Mutations occur in different types and sizes [16], and each mutation type is 
traditionally detected by a specialized technique (Figure 1). The smallest mutations 
affect only a single bp and are called point mutations or single nucleotide variants 
(SNVs) (Figure 1a). These mutations substitute one of the nucleotides Adenine 
(A), Cytosine (C), Guanine (G) and Thymine (T) for another nucleotide, like the 
mutations in OCA2 [6]. Mutations which insert or delete DNA sequences (1-1000 
bps) are called insertions and deletions, or InDels collectively (Figure 1b). An 
example of an InDel is a deletion of 3 bps in the CFTR gene which causes cystic 
fibrosis [17,18]. Larger mutations (>1000 bps) that affect the amount of DNA are 
usually referred to as copy number variants (CNVs) and classified as either gains or 
losses of genomic material (Figure 1c), for example the 600 kb loss identified in the 
17q21.31 microdeletion, or Koolen-de Vries, syndrome [19,20]. Mutations affecting 
a whole chromosome, thereby changing the number of chromosomes present in a 
cell, are called aneuploidies and occur most commonly as a trisomy (three copies 
of a chromosome) or a monosomy (one copy of a chromosome) (Figure 1d), for 
example trisomy 21 which causes Down syndrome [14]. Other, more complex, 
events can invert a piece of DNA (Figure 1e) or relocate a piece of DNA to another 
part of the genome (Figure 1f).
As mentioned previously, different mutation types are traditionally detected by 
a dedicated detection method, usually in a targeted or genome-wide manner. 
Targeted approaches are often more sensitive but can only be applied to small 
portions of the genome at a time compared to genome-wide approaches which can 
be applied even when no prior information is available about the genomic location. 
Below are two examples which illustrate how traditional techniques were applied 
and combined in studying the cause of severe early onset diseases with sporadic 
occurrence. Such disorders are typical examples of diseases where no information 
was known about the genomic location harboring the mutations responsible for the 
phenotype.
The genetic cause of CHARGE syndrome was identified after array based comparative 
genomic hybridization (aCGH), a genome-wide approach for CNV detection, identified 
a rare deletion on chromosome 8 in a patient. When the unaffected parents were 
tested for this mutation it was found to be absent in the DNA of both parents, the 
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Figure 2, Schematic representation of the contribution of de novo mutations to genetic 
disease based on various disease characteristics. 
mutations was a de novo CNV. The genomic region identified contained the CHD7 
gene which was subsequently sequenced via Sanger sequencing to identify de novo 
SNVs and InDels in additional patients with this syndrome. Sanger sequencing of a 
larger cohort revealed de novo CHD7 point mutations in a large portion (65-70%) 
of patients with the same phenotype, thereby establishing the cause of CHARGE 
syndrome [21,22]. Many other aCGH studies have shown that de novo CNVs occur 
throughout the genome and that they occur at higher frequency in individuals with 
neurodevelopmental disorders than in individuals without such a disorder [16]. 
Consequently, recurrent de novo microdeletions and microduplications are now 
recognized as a common cause of sporadic human disease [23,24]. 
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An alternative to genome-wide approaches is the so called candidate gene approach, 
where researchers choose genomic regions or genes of interest based on biological 
knowledge. This approach is applicable to sporadic disorders but requires a sound 
understanding of the biological processes involved in the phenotype. An example 
of such a candidate gene study in neurodevelopmental disorders was the Sanger 
sequencing of genes involved in synaptic plasticity, an important element of human 
cognition. The sequencing of this sub-set of genes in a large cohort of patients with 
nonsyndromic intellectual disability (ID) revealed a number of de novo mutations 
affecting the SYNGAP1 gene [25]. 
In the majority of patients with sporadic diseases however neither genome-wide 
approaches nor candidate gene strategies have been able to identify the underlying 
genetic defect. As a result, the cause of most rare sporadic genetic disorders 
remained largely undetermined. These early studies did however suggest an 
important role for de novo mutations in the sporadic occurrence of severe, early 
onset genetic diseases. 
SYSTEMATIC GENOME-WIDE IDENTIFICATION OF DE NOVO MUTATIONS
In early studies, the de novo occurrence of mutations was determined after the 
mutation was identified in a patient. In other words, researchers tested the most 
interesting mutations for their presence in either parent. A systematic search for 
de novo mutations requires the initial experiment to be performed not only on the 
child but also on both parents. Sequencing of a child and its parents is also referred 
to as trio, or family-based sequencing. The high costs of the required laboratory 
experiments meant that researchers could only perform such systematic screens in 
a subset of the genome [25,26]. Recent technological advances, including massive 
parallel sequencing (MPS), have made it possible to study the whole human genome 
in a single experiment at base pair resolution in both the patient and its parents. 
MPS is also referred to as next generation sequencing (NGS) as it represents the 
next technological revolution in sequencing after Sanger sequencing. MPS allows 
researchers to study the role of de novo mutations in disease without a priori 
knowledge of the genomic regions involved.
The use of MPS technologies also resulted in datasets much larger compared to those 
obtained through traditional Sanger sequencing. Not only did this new technique 
generate many more sequence reads, (depending on the technology fragments 
35 to 400 nucleotides long), the reads came from many different regions of the 
genome. The sheer bulk of the data combined with greater complexity required 
bioinformatic procedures to analyze the reads and identify genetic variation. 
Sequence reads had to be corrected for systematic errors, mapped to their region 
of origin on the genome and finally all sequencing reads had to be compared to the 
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reference genome to systematically identify variants. Interpreting genomic variation 
in a disease context required additional annotation and prioritization procedures to 
enable an assessment of their biological relevance. 
The most complete annotations are available for those regions of the human 
genome which encode proteins, like the OCA2 gene involved in eye color. All coding 
regions together make up approximately 1% of the genome. Mutations in these 
regions have been the focus of traditional research as changes in protein function 
can most readily be linked to changes in a patient’s phenotype [27,28]. Hence many 
researchers chose to first focus on these regions to achieve better quality and 
reduce sequencing costs. The sequencing of all coding regions simultaneously is 
called whole exome sequencing (WES). Researchers first capture the coding regions 
using oligonucleotide probes after shearing the DNA into small pieces. This process 
of enrichment greatly increases the representation of coding regions in the final 
sequencing experiment. 
WES was first successful in 2010 by the discovery of the genes mutated in both 
a rare autosomal recessive and a dominant disorder [29,30]. Since these initial 
studies, many groups have applied WES successfully to identify numerous other 
disease genes [31–33] and have confirmed the important role of de novo point 
mutations underlying rare sporadic disease [30,34–42]. Additionally, by studying de 
novo point mutations in the context of common neurodevelopmental disorders, a 
new paradigm emerged, accounting for the high prevalence of neurodevelopmental 
disorders associated with reduced fitness [chapter 2,43–45]. 
Through the systematic analysis of de novo mutations several factors have been 
identified which play a role in the occurrence of disease through de novo mutations. 
These factors are the per generation mutation rate, target mutability and target 
size. At the same time, the genetic architecture of the trait (familial or sporadic, 
monogenic or complex, normal or reduced fitness of patients) all affect the relative 
contribution of de novo mutations to the disease (Figure 2). Here we provide 
an overview of how these factors influence the occurrence and role of de novo 
mutations in disease, focusing on small mutations as these have only recently been 
studied. 
THE HUMAN GERMLINE MUTATION RATE
An important factor which determines the frequency of germline de novo mutations 
is the per generation mutation rate. Prior to the NGS era, studies on mutation rates 
focused on specific genes [13,46,47]. For instance, the evaluation of 20 loci involved 
in Mendelian diseases yielded a direct estimate of 1.8 x 10-8 point mutations per 
nucleotide per generation. This indicated that single nucleotide substitutions were 
25 times more common than all other mutations [47–49]. In 2010, a first systematic 
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Figure 3, Schematic representation of the relation between the contribution of de novo 
mutations to disease type and prevalence. Orange shading reflects the impact of de novo 
mutations, with darker shading indicating a more prominent role for de novo mutations in 
diseases with these characteristics.
study investigated the occurrence of de novo point mutations in patients with 
neurodevelopmental disorders by resequencing >400 candidate disease genes. This 
study suggested an equal number of de novo mutations in patients and controls but 
showed an excess of deleterious mutations in patients [43].
The availability of direct measurements of large amounts of DNA sequence has led 
to a more accurate determination of the human germline mutation rate [50,51] 
which has proven to be close to its early estimates [47,52]. The current best estimate 
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of the human germline point mutation rate is 1.18 x 10-8 per nucleotide, which 
corresponds to 74 de novo point mutations throughout the genome per generation 
[16]. In contrast, the larger mutation types have lower germline mutation rates, 
4×10−10 for InDels [53] whereas large (>100kb) CNVs occur approximately in only 1 
out of every 50 individuals [54].
Genomic positions that frequently mutate, so called mutation hotspots, were found 
to have only a minor contribution to overall human mutation rates [51]. Interestingly, 
Conrad and colleagues [51] showed substantial variation in the germline mutation 
rate, not only between families, but also within a family. Also, several WES studies 
in autism have reported an increased number of de novo point mutations as well as 
an excess of deleterious de novo point mutations in patients compared to controls 
[55,56]. These observations may, in part, be explained by a recent large-scale 
parent-offspring study that was able to demonstrate that the number of de novo 
germline mutations increases with advancing paternal age [57] (see also section on 
the impact of parental age on the occurrence of de novo mutations). Comparison 
of various large-scale sequencing studies [44,55,58,59] indicates that of all de novo 
point mutations, an average of 1.19 mutations per generation affect the coding 
sequence. A large fraction (~78%) of the mutations affecting the coding sequence 
is predicted to alter the protein sequence [16], possibly altering protein function.
The per generation germline mutation rates discussed here provide insights into 
the average number of mutations which occur but do not address the underlying 
mechanisms. The mutational mechanisms do however determine the likelihood 
that a certain region is mutated, or target mutability.
TARGET MUTABILITY
In principle DNA copying errors, and therefore mutations, occur randomly. However, 
the probability of mutation at a given site is not uniform across the genome [60]. 
Regional mutation rates are subject to a variety of genomic characteristics [61] and 
influenced by external factors such as parental age [57,62,63] (see the parental age 
section). Large differences in mutational rate are particularly evident for structural 
variation (SV) for which mutation rates have been observed to vary between 
10-4 and 10-6 mutations per base per generation [64]. Some of these differences 
can be explained by SV hot spots, where recurrent mutations are mediated 
by nonallelic homologous recombination (NAHR) between tandem segmental 
duplications [65,66]. Regional rates of nucleotide substitution are also variable [61] 
which depends on a large number of factors [60]. In contrast to the SV hot spots 
(predominantly driven by meiotic recombination) nucleotide substitution can occur 
by a variety of mechanisms, and the mutation rate is influenced to a much greater 
extent by mitotic mechanisms [62].
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Table 1, The effect of the mutational target size and de novo point mutations on the 
frequency of disease 
Estimated 
mutational target 
size
Example genetic 
disorder name 
(Gene)
Observed disease 
frequency 
(x/100,000)
Expected de novo 
mutation frequency 
for target 
(x/100,000)
1 nucleotide 
(bp)
New ID syndrome
(PACS1) <0.001 a 0.0019 d
11 nucleotides (bps) Schinzel-Giedion (SETBP1) <0.01 a 0.021 d
~300 nucleotides 
(bps) *
Noonan 
(>6 genes) 50 b 0.58 d
1 gene CHARGE (CDH7) 0.14 b 0.26 e,f
~500 genes Severe ID 300-500 c 601 f,g
* The mutational target size for Noonan syndrome was adjusted from the original publication 
to better reflect the gain of function mechanism of this disease, to date 92 codons have 
been implicated in Noonan syndrome [Uniprot, accessed 01-08-2013] assuming that 2 bases 
in each codon can cause the disease when mutated and that current knowledge explains 
approximately 60% of cases [76] results in an estimated target size of 307 base pairs to 
explain 100% of the cases. 
Of note, observed frequencies exceeding the expected frequency due to de novo mutations 
may indicate familial occurrence, clonal expansion in spermatogenesis and/or other genetic 
factors playing a role, whereas observed frequencies lower than expected may suggest 
embryonic lethality.
a. Based on the number of currently published cases. 
b. Derived from; rare disease frequency report of ORPHANET [101].
c. Estimated mutation target size as reported by Leonard and Wen [15].
d. An average non-synonymous germline mutation rate of 0.58 per generation [16].
e. An average truncating germline mutation rate of 0.055 per generation [16].
f. The expected frequency of a disease in the population was based on the following 
assumptions:
• an average coding gene size of 1419 base pairs
• de novo point mutations occur randomly in the coding sequence
g. To estimate the number of mutations functionally affecting genes, a causal mutation 
rate of 0.252 per generation was used, based on 0.055 + (0.58 × 0.34); the average 
truncating mutation rate plus 34% [102] of the average non-synonymous germline 
mutation rate.
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Germline de novo point mutations have been found to show nonrandom occurrence 
in the genome. Compared to a random mutation model de novo mutations are 
spaced more closely than expected [60]. Closely spaced de novo mutations, called 
mutation pairs, were observed to have a single parent of origin, consistent with 
mutations arising in a single replication event [67]. Clusters of two or more de novo 
mutations within 100 kb of each other occur approximately once per generation 
[60]. The occurrence of such clusters could be explained by compound mutation or 
by de novo nucleotide substitutions that occur during allelic gene conversion events 
[68,69].
Numerous genomic features have been found to influence site mutability, of which 
the most significant are DNase hypersensitivity, GC content, nucleosome occupancy, 
recombination rate, trinucleotide sequence content and simple repeats surrounding 
the site [60]. Most de novo mutations constitute transitions (purine ↔ purine and/
or pyrimidine ↔ pyrimidine) rather than transversions (purine ↔ pyrimidine). 
Cytosine phosphate Guanine (CpG)-rich regions are enriched for de novo mutations 
as indicated by an elevated mutation rate of 1.5 x 10-8 per nucleotide [13,48,49,56], 
occurring most often on CpG dinucleotides [60]. Germline methylation further 
influences the substitution rate at these CpG sites [70]. The elevated mutation rate 
in GC-rich regions may have consequences for human disease as most disease-
causing mutations identified to date are located in coding sequences, which are GC 
rich. 
THE ROLE OF GERMLINE DE NOVO MUTATIONS IN RARE GENETIC DISEASE
The search for disease-causing de novo mutations in rare sporadic syndromes has 
been accelerated considerably by WES. The cause of Kabuki syndrome (MLL2) 
[34] was described, and the gene for Schinzel Gieion Syndrome was identified 
the same year by de novo mutations in SETBP1 for 12 of 13 patients [30]. Many 
successes followed, including, Hajdu-Cheney syndrome (NOTCH2) [35,36], KBG 
syndrome (ANKRD11) [37], Baraitser-Winter syndrome (ACTB and ACTG1) [38], 
Coffin-Siris syndrome (components of the SWI/SNF complex) [39,40], and Cantù 
syndrome (ABCC9) [41,42]. These studies have shown that sporadic diseases are 
now amenable to genetic disease research. An important success factor in these 
studies was careful selection of a homogeneous groups for analysis by thorough 
phenotypic characterization of patients. The proper grouping of patients leads to 
greater similarity in the underlying disease mechanism and thereby the underlying 
genetics. For rare Mendelian disorders, exome sequencing the DNA of three 
to four well-phenotyped patients combined with an analysis to identify de novo 
point mutations in the same gene, or gene(s) in the same pathway, is sufficient 
to discover the genetic cause of disease [39,40,71,72]. Similarly, a WES study of 
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two unrelated patients with ID and a striking facial resemblance suggestive of a 
hitherto unappreciated syndrome identified the exact same de novo point mutation 
in PACS1 in both of them, underscoring the need for detailed phenotyping [73]. To 
facilitate the identification of such syndromes, data sharing at international level 
for both genotypes as well as phenotypes is of utmost importance (see also section 
below on de novo point mutations in common genetic disease and chapter 6).
These studies also provided insight in the interactions between fitness, severity 
of disease and the role of de novo mutations. In KBG syndrome the majority of 
sporadic patients were shown to have a de novo mutation in ANKRD11, however 
one mutation segregated with disease in a family [37]. This family was reported to 
have a less severe ID phenotype, which potentially decreased the selective pressure 
on this mutation. Similarly, severe late onset genetic disorders, such as Alzheimer 
Disease, have little to no effect on reproductive fitness, allowing pathogenic 
mutations to spread through the population [74], thereby decreasing the relative 
contribution of de novo mutations to disease (Figures 2 & 3). It has to be noted that 
a comprehensive analysis of de novo mutations in late-onset neurodegenerative 
disorders is hampered by the fact that patients with these diseases usually do not 
have surviving parents who can supply DNA samples for inheritance analysis [75].
MUTATIONAL TARGET SIZE AND DISEASE FREQUENCY
The frequency of de novo mutations causing a certain disease reflects the number 
and size of the genomic regions that are involved. The aggregate of these regions 
is also known as the mutational target. The chance that random de novo mutations 
affect a target is largely determined by the targets size (Figure 2). For example in 
SETBP1, the gene involved in Schinzel-Giedion syndrome, all pathogenic de novo 
point mutations were contained within an 11 base pair stretch [30]. This strong 
clustering of mutations results in a very small mutational target, which predicts that 
this syndrome should be extremely rare. Its frequency is determined by the chance 
that one of the approximately 74 de novo germline point mutations affects this 11 
base pair locus. The chance of hitting the target should be even lower when a disease 
is caused by mutation of only one specific base, as was recently described for PACS1 
[73]. In the case of PASC1 only two patients worldwide have been recognized with 
this syndrome so far, although other patients must surely exist [73]. 
In contrast to rare genetic disorders, the central hypothesis for common diseases has 
been that they can be caused by common genetic variants which are detectable by 
adequately powered genome-wide association studies (GWAS). De novo mutations 
affecting a large mutational target of hundreds, or even thousand(s), of genes could 
collectively cause a common genetic disease (Figure 3). 
Random modeling of de novo mutations for well-known monogenic diseases, with 
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and without locus-heterogeneity, indicates that the frequency of diseases caused 
by de novo point mutations indeed mostly reflects the mutational target size (Table 
1). Notably, it may be hypothesized that the mutational target size will provide 
insight into the complexity of the underlying process. More specifically, the high 
prevalence of neurodevelopmental disorders might reflect the complexity of the 
central nervous system, which is regulated by many different pathways. Hence, 
every gene that regulates, or is a part of, these pathways may contribute to disease 
when mutated.
Assuming target size as the main determinant, we can see that a large discrepancy 
exists for Noonan syndrome between the expected and observed disease frequency 
(Table 1). This may in part be due to the familial occurrence of this disorder [76] 
but familial transmission of Noonan is relatively rare, and can certainly be only 
a minor factor in its high prevalence. A more likely cause is clonal expansion of 
Noonan syndrome gene mutations in the spermatogonia [77]. This spermatogonial 
expansion correlates strongly with paternal age [26,77] and is discussed in more 
detail in the parental age section.
Generally speaking, gain-of-function or dominant negative disease mechanisms 
create smaller mutational targets than do loss of function mechanisms. For example, 
all mutations involved in Schinzel-Giedion syndrome were confined to an 11 base 
pair stretch which may be indicative for a gain-of-function mechanism [30]. This 
notion is further supported by the identification of other clinical entities in which 
SETBP1 plays a role; deletions including this gene contribute to the 18q contiguous 
gene deletion syndrome [78], whereas truncating mutations have been implicated 
as a cause of autism spectrum disorders (ASDs) and nonsyndromic intellectual 
disability [79,80]. These genotype-phenotype correlations based on the underlying 
pathophysiological mechanism are well-known in other diseases [81] and will have 
a large effect on disease frequency.
DE NOVO MUTATIONS IN COMMON GENETIC DISEASE
Prior to the introduction of NGS, the large degree of locus-heterogeneity complicated 
a comprehensive study of rare and de novo point mutations in common disease, 
such as for instance ID, and ASD. In earlier studies genome-wide approaches such 
as GWAS and aCGH have implicated many loci in such complex disorders, but these 
often required additional follow-up to elucidate the underlying cellular mechanism 
[65,82]. Using family-based WES approaches, a number of studies have recently 
supported the hypothesis that de novo mutations indeed affect a wide variety 
of genes and that these events collectively play an important role in common 
neurodevelopmental diseases such as ID [chapter 2 & 3,80], ASDs [44,58,59,79] 
and schizophrenia [43,45,83].
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The first systematic family-based WES study of 10 patients with severe ID identified 
possibly causal de novo mutations in 6 out of 10 patients and thereby established a 
de novo paradigm for ID [chapter 2]. Two larger studies subsequently found causal 
deleterious de novo point mutations in 13-36% of sporadic patients with severe 
ID [chapter 3, 80]. A large number of other patients carried de novo mutations in 
genes with a role in brain development or function but which, had not previously 
been found mutated in ID. If all these candidates genes would be relevant for ID, 
the percentage of patients with causal de novo point mutations may rise as high 
as 32-60% [chapter 3, 80]. Similarly, based on initial studies in known disease 
genes, de novo point mutations seem to contribute to ASDs and schizophrenia 
[43,45,58,59,79,83] albeit with a lower impact than in severe ID. A WES study of 
sporadic schizophrenia patients did not reveal mutations in known schizophrenia 
genes but yielded candidate genes with presumably causal de novo point mutations 
in 17% of cases [45,83]. Three other large-scale studies used WES to study the role 
of de novo mutations in ASDs [58,59,79]. The studies identified 2-4% causal de novo 
point mutations in known and novel ASDs associated genes. Although the exact 
number of candidate genes for ASDs is unclear due to the different criteria used 
for candidate classification, 20 to 50 novel ASDs genes may be defined. Attributing 
causality to the candidate genes would increase the contribution of de novo point 
mutations in ASDs to approximately 17%. 
The results for ID, ASD and schizophrenia collectively underscore the importance 
of de novo mutations for common genetic disorders as well as the need for follow-
up studies to establish the relevance of (de novo) mutations in candidate disease 
genes. A complicating factor for interpretation is that many de novo mutations in 
candidate genes involve missense mutations for which it is difficult to establish 
pathogenicity and specific disease mechanisms without additional functional 
follow-up of each mutation individually. Current software prediction tools, such as 
SIFT [84], PolyPhen-2 [85], Condel [86] and MutationTaster [87], are not sufficiently 
robust to provide a reliable and unambiguous prediction on mutation impact [88]. 
For monogenic disorders proving causality has been less of a challenge as 
researchers can rely on the detection of mutations in the same gene in patients 
with overlapping phenotypes [30,34–42]. For diseases with a larger degree of locus 
heterogeneity, efforts have been put in targeted re-sequencing of candidate genes 
to increase the chance of finding additional mutations [chapter 3,79,83,89]. The 
success of this approach relies heavily on the patient cohort selected, and thus 
on (deep-) phenotyping of patients using standardized nomenclature such as the 
human phenotype ontology (HPO) [90]. 
Clinically well-defined patient cohorts also facilitate reverse-phenotyping, where 
phenotypes are (re-)defined based on genetic information that has become available. 
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For instance, we recently found two patients in different studies with severe ID and 
a de novo mutation in DYNC1H1 [chapter 2 & 3]. Re-evaluation of the phenotypes of 
these patients revealed a neuronal migration defect and other clinical similarities, 
thereby potentially defining a new syndrome [91]. There are likely many more 
“recognizable clinical entities within a common disease”, which predicts that many 
novel syndromes will be delineated in the near future. The availability of precise 
and accurate phenotypes is of special importance given the fact that recurrence 
of certain de novo mutations may only be identified by examining patients from 
across the globe, especially for small mutational targets. Disease (gene) discovery 
may therefore benefit from ongoing efforts to sustain databases that contain both 
detailed phenotypes as well as genotypes. It is important that these databases 
can also contain different forms of genetic variation [chapter 4,92,93]. In addition, 
functional studies remain essential In order to establish the pathogenic nature of 
de novo mutations and to understand the pathogenic mechanisms involved. An 
example is the mechanism by which de novo missense mutations of ABCC9 cause 
Cantù syndrome [42].
THE IMPACT OF PARENTAL AGE ON THE OCCURRENCE OF DE NOVO MUTATIONS
Down syndrome, is one of the most common and well known disorders associated 
with ID and parental age [94]. John Langdon Down defined the syndrome in 1866. In 
1959 Jérôme Lejeune was able to count the chromosomes of healthy and affected 
individuals, referred to as karyotyping, with the use of a revolutionary technique in 
tissue culturing. He observed that all affected individuals had three copies, called 
a trisomy, of chromosome 21 rather than two copies as observed in unaffected 
individuals. This experiment identified the genetic cause underlying Down 
syndrome and provided a first molecular diagnosis for ID. More detailed studies on 
whole chromosome abnormalities, aneuploidies, found a strong bias in parental 
origin, events being mostly of maternal origin and subsequently the occurrence rate 
was found to be associated with maternal age [94], these observations have led to 
screening for trisomies in pregnancies after the age of 36 years in the Netherlands 
[95]. More recently, it has become apparent that the identification of trisomy 21 is 
also possible in a non-invasive manner using MPS [96,97, chapter 5]. This technique 
relies on the presence of fetal DNA material in the blood circulation of the pregnant 
women [96]. The quantification of the maternal and fetal DNA simultaneously 
allows researchers to measure relative abundances of different chromosomes [96], 
further discussed in chapter 5.
In contrast to aneuploidies mostly being of maternal origin, recent large-scale 
sequencing studies have shown that approximately 80% of de novo point mutations 
occur on the paternally-derived chromosome [44,57]. Further, the majority of de novo 
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CNVs appear to be of paternal origin [63]. In general, a strong correlation between 
paternal age and the number of de novo point mutations has now been established 
[57]. For the common male reproductive period (20-40 years, with an average age 
of 29.7) the number of de novo mutations in the offspring is estimated to increase 
by ~4% each year [57]. This corresponds to two additional de novo mutations on an 
annual basis and a doubling of the total number of de novo mutations every 16.5 
years [57]. As de novo point mutations occur more often in Guanine and Cytosine 
(GC) rich regions (see section on target mutability), the increase in the number of 
mutations in coding regions might be even higher. Assuming a two-fold increase in 
de novo mutations with advanced paternal age would result in a two-fold increase 
in genetic diseases caused by de novo mutations. This elevated risk may be even 
stronger if other genetic as well as gestational and environmental factors are taken 
into account [98]. 
To estimate the relative increased risk of a genetic disorder with advanced paternal 
age the contribution of mutation and of inheritance must be considered. In the case 
of Schinzel-Giedion, caused by de novo missense mutations in a mutational target 
of 11 base pairs, we can assume that all cases reflect de novo events. Using the 
non-synonymous germline mutation rate of 0.58 per generation [16], and assuming 
that all de novo point mutations leading to this disease are of paternal origin, a two-
fold increase in the number of de novo mutations will be equivalent to a two-fold 
increase in risk of the disorder from 0.021 to 0.042 in every 100,000 live births. More 
complex disorders, such as ASDs or mild ID, are considered only partly genetic and 
only a portion of the genetic contribution is explained by de novo mutations. Hence, 
a two-fold increase in de novo mutations may only slightly raise the occurrence of 
these diseases. Nonetheless, it is tempting to speculate that the apparent increase 
in incidence and prevalence of neurodevelopmental conditions such as ASDs could 
partly be due to the accumulation of mutations in the population as an effect of 
advancing paternal age [99]. There is an important class of disorders for which 
the paternal age effect is much stronger. This includes FGFR2 mutations for Apert 
Syndrome and FGFR3 mutations for achondroplasia and thanatophoric dysplasia 
[100]. For these so called “paternal age effect” disorders, de novo mutations are 
positively selected and expand clonally in normal testes through a process similar to 
oncogenic expansion [26]. Positive germline selection has also been demonstrated 
for Noonan syndrome (Table 1) [77]. It is important to note that all mutations 
that appear to show this phenomenon of testicular selection by clonal expansion 
are implied in oncogenic pathways, and have gain of function effects. It may be 
expected that further examples exist possibly also including neurodevelopmental 
disorders [26].
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GENERAL CONCLUSIONS
New technologies have enabled the genome-wide evaluation of genetic variation 
and this has established that de novo germline mutations are a major cause of 
monogenic diseases with a severe impact on reproductive fitness in both rare and 
common disorders. The clinical interpretation of rare de novo missense variants 
remains a challenge as and requires a combination of deep-phenotyping, testing for 
recurrently mutated genes, functional approaches and international data-sharing 
to further our understanding of genetic disease [chapter 6]. 
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The term ‘mental retardation’ was used until 2010, when Rosa’s Law was passed in the United 
States on October 5th, this law states that the term is replaced by ‘intellectual disability’. This 
change of terminology has been almost universally accepted by the scientific community. 
The term ‘mental retardation’ is used in chapter 2 as we have left it in its original format, the 
publication was drafted before the law was passed and published as such.
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The per-generation mutation rate in humans is high. De novo mutations may 
compensate for allele loss due to severely reduced fecundity in common 
neurodevelopmental and psychiatric diseases, explaining a major paradox in 
evolutionary genetic theory. Here we used a family based exome sequencing 
approach to test this de novo mutation hypothesis in ten individuals with 
unexplained mental retardation. We identified and validated unique non-
synonymous de novo mutations in nine genes. Six of these, identified in six different 
individuals, are likely to be pathogenic based on gene function, evolutionary 
conservation and mutation impact. Our findings provide strong experimental 
support for a de novo paradigm for mental retardation. Together with de novo 
copy number variation, de novo point mutations of large effect could explain the 
majority of all mental retardation cases in the population.
Recent studies [1,2] have indicated that humans have an exceptionally high per-
generation mutation rate of between 7.6×10−9 and 2.2×10−8. An average newborn is 
calculated to have acquired 50 to 100 new mutations in his or her genome, resulting in 
approximately 0.86 new amino-acid–altering mutations [2]. Spontaneous germline 
mutations can have serious phenotypic consequences when they affect functionally 
relevant bases in the genome. In fact, their occurrence may explain why diseases 
with a severely reduced fecundity remain frequent in the human population, 
especially when the mutational target is large and comprised of many genes. 
This would explain a major paradox in the evolutionary genetic theory of mental 
disorders [3,4]. In agreement with this hypothesis, de novo copy number variations 
(CNVs) are a known cause of schizophrenia, autism and mental retardation [5,6]. 
Much less is known about the frequency and impact of de novo point mutations 
in these common diseases. Whole genome or exome sequencing now permits the 
study of these mutations and their role in disease in a systematic genome-wide 
manner. This approach has recently been used to identify causative genes in several 
rare syndromes [1,7–10]. In addition, targeted resequencing of the coding exons of 
the X chromosome revealed nine genes associated with X-linked forms of mental 
retardation [11], showing the strength of these analyses in common diseases. In 
this study, we used a family based whole-exome sequencing approach to test the 
de novo mutation hypothesis in an unselected cohort of individuals with mental 
retardation.
We sequenced the exomes of ten case-parent trios. All cases, eight males and two 
females, had moderate to severe mental retardation and a negative family history. 
Clinical evaluation did not lead to a syndromic or etiologic diagnosis (Supplementary 
Online Note). Prior cytogenetic analysis showed normal chromosomes, and array-
based genomic profiling did not reveal de novo or other CNVs associated with mental 
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retardation. In addition, fragile X syndrome was excluded by FMR1 repeat expansion 
analysis. On average, we obtained 3.1 Gb of mappable sequence data per individual 
after exome enrichment (37 Mb of genomic sequence targeting ~18,000 genes) and 
sequencing on one quarter of a SOLiD sequencing slide (Supplementary Methods 
and Supplementary Table 1). Color space reads were mapped to the reference 
genome. On average, 79.6% of the bases originated from the targeted exome, with 
90% of the targeted exons covered at least ten times. The median exon coverage 
was 42-fold, indicating that the majority of variants present in each exome could be 
robustly detected using a custom bioinformatic analysis pipeline (Supplementary 
Figure 1). On average, we identified 21,755 genetic variants per individual with high 
confidence (Table 1 and Supplementary Figure 2).
We developed an automated prioritization scheme to systematically identify all 
candidate dominant de novo mutations in each affected individual (Figure 1). We 
first excluded all, intronic and synonymous variants other than those occurring 
at canonical splice sites. This first step reduced the number of candidates to an 
average of 5,640 non-synonymous and canonical splice site variants per affected 
individual. We further reduced this number to 143 by excluding all known, likely 
benign, variants by comparison with data from dbSNP database v130 and our in-
house variant database. Next, we used the exome data from each case’s parents to 
exclude all remaining inherited variants. This resulted in an average of five (with a 
range of two to seven) candidate de novo non-synonymous mutations per affected 
individual (Table 1).
For all 51 candidate mutations (Supplementary Table 2), we performed Sanger 
sequencing to (i) validate the mutations observed in the probands and (ii) validate 
the absence of the mutations in the parental DNA. Thirty-eight candidates could 
not be validated in the proband (covered by a median of five variant reads in the 
exome sequencing experiment), but 13 candidates could be validated (covered by 
a median of 17 variant reads). Parental analysis validated the de novo occurrence 
for 9 of these 13 mutations, detected in seven different individuals (Table 2 and 
Supplementary Figures 3 & 4). We did not identify these mutations in a total of 1,664 
control chromosomes, nor did we see other likely pathogenic mutations identified 
in the affected genes in these control chromosomes, indicating that the population 
frequency of these types of de novo mutations in these genes will be lower than 
0.22% (power=0.95, α=0.05). Eight of the de novo mutations were present in a 
heterozygous state on the autosomes and one was present in a hemizygous state 
on the X chromosome. All de novo mutations occurred in different genes, including 
two genes recently implicated in mental retardation (Table 2). In addition to using 
a dominant disease model, we also analyzed the data for recessive forms of mental 
retardation. In the affected male of trio 10, we identified a maternally inherited non-
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Figure 1, Experimental work flow for detecting and prioritizing sequence variants. For all 
ten mental retardation trios, prioritization of variants observed in the probands was based 
on selection for non-synonymous changes of high quality only and exclusion of all variants 
previously observed in healthy individuals, together with those variants that were inherited 
from an unaffected parent. Interpretation of de novo variants was based on gene function 
and the impact of the mutation.
synonymous variant in JARID1C (Table 2), which is a well-described X-linked mental 
retardation gene [12]. Subsequent analysis of this variant in DNA obtained from 
the affected individual’s grandparents indicated that the mutation had occurred de 
novo in the mother of this proband. No conclusive evidence for autosomal recessive 
inheritance, either homozygous or compound heterozygous, was obtained for the 
other affected individuals.
Next, we evaluated the function of each mutated gene in relation to the disorder 
(Table 2). Three genes do not seem to play a role in biological pathways linked to 
mental retardation. BPIL3 is involved in the innate immune response [13], whereas 
PGA5 is involved in protease activity in the stomach [14]. The function of ZNF599 
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is currently unknown. For the six other genes affected by de novo mutations, 
functional evidence suggests a role in mental retardation. Two mutations occurred 
in genes (RAB39B and SYNGAP1) that, when disrupted, are known to cause mental 
retardation (Table 2) [15,16]. For the remaining four mutated genes, evidence for 
a causal link with mental retardation is provided by model organisms and protein-
protein interaction studies. DYNC1H1 encodes a cytoplasmic dynein that acts as 
a motor for intracellular retrograde axonal transport. Heterozygous Dync1h1+/− 
mutant mice exhibit sensory neuropathy [17], and studies in zebrafish have shown 
the importance of dync1h1 in correct nuclear positioning. Mislocalization of nuclei 
in the vertebrate central nervous system is likely to result in profound patterning 
defects and severely compromised function [18]. Notably, DYNC1H1 interacts 
with PAFAH1B1, the gene associated with type I lissencephaly, which involves 
gross disorganization of the neurons within the cerebral cortex [19]. YY1 encodes 
the ubiquitously expressed transcription factor yin-yang 1 and directs histone 
deacetylases and histone acetyltransferases, implicating chromatin remodeling as its 
main function. Complete ablation of Yy1 in mice results in early embryonic lethality, 
whereas Yy1 heterozygous mice display growth retardation, neurulation defects and 
brain abnormalities [20]. Recent studies show that YY1 interacts directly with MECP2; 
MECP2 is mutated in Rett syndrome [21]. DEAF1 encodes a transcription factor that 
regulates the 5-HT1A receptor in the human brain. Mutations in the Drosophila 
DEAF1 ortholog result in early embryonic arrest, suggesting an essential role for the 
gene in early development [22]. Additional evidence is provided by Deaf1-deficient 
mice, which show neural tube defects including exencephaly [23]. Finally, CIC is a 
member of the HMG-box transcription factor superfamily, which is associated with 
neuronal and glial development of the nervous system. CIC is predominantly and 
transiently expressed in immature granule cells of the cerebellum, hippocampus 
and neocortex, suggesting a critical role in central nervous system development 
[24].
We next examined the evolutionary conservation of affected nucleotides (using 
the phyloP score), as well as the potential of the de novo mutations to affect the 
structure or function of the resulting proteins (using the Grantham score; Table 2). 
All de novo missense mutations and the inherited X-linked mutation were included 
in this analysis; no Grantham scores were available for the additional nonsense and 
frameshift mutations. Of note, de novo mutations in genes with a functional link 
to mental retardation showed a higher phyloP (mean, 4.7) and Grantham score 
(mean, 135) than mutations in genes without such a functional indication (mean 
phyloP score −0.5 and mean Grantham score 38). We also compared these scores 
to those for all non-synonymous variants in the dbSNP database as well as those 
in the Human Gene Mutation Database (HGMD). The distribution of phyloP scores 
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and Grantham scores differed markedly between dbSNP and the HGMD (Online 
Methods and Supplementary Figure 5). The four mutations in genes functionally 
linked to mental retardation all showed higher probability values for being observed 
in HGMD (mean 0.83) than for being observed in dbSNP (mean 0.17). The three 
mutations in genes without a functional link to mental retardation showed an 
average probability of 0.94 for being observed in dbSNP and an average probability 
of 0.06 for being observed in HGMD (Table 2). Additionally, the inherited JARID1C 
mutation showed a probability of 1.00 for being in HGMD versus 2.09 × 10−6 for 
being in dbSNP.
This analysis of the mutated nucleotides and their impact on gene function strongly 
supports pathogenicity for six of the nine de novo mutations. Importantly, these six 
mutations occurred in genes with a functional link to mental retardation, two of 
which are known mental retardation genes. In contrast, three de novo variants in 
genes without a functional link did not appear to significantly affect protein function. 
Moreover, we identified a maternally inherited mutation in a known X-linked mental 
retardation gene that arose de novo in the proband’s mother. Although we have 
not provided individual functional tests to prove causality, these data collectively 
provide strong evidence for a major role of de novo mutations in mental retardation. 
The identification of recurrent mutations in these genes in unrelated cases would 
provide additional proof for disease causality, but this may require the evaluation of 
thousands of affected individuals. The identification of subtle CNVs encompassing 
(part of) these genes may also provide additional proof for disease causality, as was 
shown recently for mutations in X-linked mental retardation genes [25]. As of yet, 
no such CNVs have been reported, nor have we found such CNVs in our diagnostic 
cohort of ~4,500 individuals with mental retardation (data not shown).
The discovery of nine de novo non-synonymous mutations in this cohort of ten 
affected individuals is concordant with the recently estimated background mutation 
rate of 0.86 amino-acid–altering mutations per newborn in controls [2], but it will 
be important to compare this result to similar data from healthy control trios when 
available. Notably, after applying the same systematic filtering approach and Sanger 
sequencing, we could only validate a single de novo synonymous mutation, which 
occurred in GRIN1 (c.351C>T, seen in trio 10). This base pair is not conserved through 
evolution (phyloP score=−3.2) and does not seem to alter splicing, suggesting that 
this mutation is an unlikely candidate for causing mental retardation. 
Of note, the individual carrying this mutation also carries the JARID1C mutation. The 
observed ratio of non-synonymous to synonymous de novo mutations is far greater 
than would be expected for protein-coding genes under purifying selection and 
indicates that many of these mutations will result in a reproductive disadvantage. 
In contrast, the average non-synonymous to synonymous ratio reported in dbSNP 
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for the six genes with predicted pathogenic mutations is significantly lower than 
that of the three genes with mutations reflecting the background mutation rate 
(Fisher’s Exact test, p=0.0016), which is to be expected for disease genes in the 
normal population.
In summary, our results suggest that de novo mutations are a major cause of 
unexplained mental retardation. These mutations can readily be identified using 
a family based exome sequencing approach and require only limited follow-up by 
Sanger sequencing. Our findings have implications for preventive and diagnostic 
strategies in mental retardation. Systematic genome-wide resequencing in parent-
child trios may uncover further examples of this de novo paradigm for other human 
neurodevelopmental disorders.
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ONLINE METHODS
SUBJECTS
Ten individuals with unexplained moderate to severe mental retardation (with 
normal karyotypes and genomic profiles obtained using 250K SNP arrays) were 
selected for exome sequencing (Supplementary Note). Family history for mental 
retardation was negative for all cases. Nongenic causes for mental retardation, 
including pre-, peri- and post-natal infection and perinatal injury, were excluded. 
DNA was obtained from peripheral blood from the ten probands as well as from 
their unaffected parents. DNA isolation was performed using QIAamp DNA Mini 
Kit (QIAGEN), according to the instructions of the manufacturer. This study was 
approved by the Medical Ethics Committee of the Radboud University Nijmegen 
Medical Centre, and all participants signed written informed consent.
LIBRARY GENERATION
Exome enrichment required 3 μg of genomic DNA, and an AB SOLiD Optimized 
SureSelect Human Exome Kit (Agilent) was used for enrichment, containing the 
exonic sequences of ~18,000 genes and covering a total of ~37 Mb of genomic 
sequence, as specified by the company. We followed the manufacturer’s instructions 
(version 1.5) for enrichment with a minor modification, which was the reduction of 
the number of post-hybridization ligation-mediated PCR cycles from 12 cycles to 9 
cycles.
SOLID SEQUENCING
The enriched exome libraries were subsequently used for emulsion PCRs, following 
the manufacturer’s instructions (Life Technologies), based on a library concentration 
of 1 picomolar (pM) (version March 2010). For each sample, one-quarter of a 
sequencing slide (Life Technologies) was used on a SOLiD 3 Plus System.
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MAPPING OF VARIANTS
Color space reads were mapped to the hg18 reference genome with the SOLiD 
bioscope software v1.2, which utilizes an iterative mapping approach. Single-
nucleotide variants were subsequently called by the diBayes algorithm26 using high 
stringency settings, requiring calls on each strand. Small insertions and deletions 
were detected using the SOLiD Small Indel Tool. We assumed a binomial distribution 
with a probability of 0.5 of sequencing the variant allele at a heterozygous position. 
Under this assumption, at least ten reads are required to obtain a 99% probability 
that at least two reads contain the variant allele. Variants and indels were selected 
using strict quality control settings, which included the presence of at least four 
unique variant reads (that is, having different start sites), as well as the variant being 
present in at least 15% of all reads. All called variants and indels were combined 
and annotated using a custom analysis pipeline (resulting in HCDiff files for each 
individual). 
CUSTOM BIOINFORMATIC ANALYSIS PIPELINE
All variants reported in the HCDiff files were filtered to ensure an optimal 
prioritization process. For this, we first excluded all nongenic, intronic (other than 
canonical splice sites) and synonymous variants, reducing the number of variants 
to an average of 5,640 per individual. Second, all known variants were excluded 
by comparison with data from dbSNP v130 as well as from our in-house variant 
database. At the time of this study, this in-house database contained variants from 
(i) 78 in-house performed ‘exomes’, contributing 515,480 variants, and (ii) the 1000 
Genomes Project (see URLs) and published data from various other studies [27–
29], contributing 3,059,835 variants, thereby bringing the number of variants in 
the in-house database to 3,525,278. Of note, if the variant observed in the proband 
occurred at a genomic position known in dbSNP v130, but the change present was 
different in the two (for example, A/C in dbSNP but A/T in the proband), the variant 
was not excluded from analysis. The filtering step using this data further reduced 
the average number of variants to 143 per proband.
Next, for a dominant model of disease, we used the exome data from accompanying 
parents to exclude all inherited variants. This step further reduced the number 
of potential de novo variants to an average of 33 per proband. As not all variants 
identified in the exomes of the probands may have been sequenced at sufficient 
coverage in the parental samples, we checked all remaining variants in the exome 
data from the accompanying parents. In brief, even if only a single read showed 
the variant allele in one of the parental exome samples, the variant was excluded 
for validation in the proband. Simultaneously, we checked all remaining potential 
de novo indels for annotation differences in each child-parent trio and excluded 
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those that were found to be identical variants in both parent and child. After this 
final check, an average of five potential de novo variants per proband remained for 
further validation.
To evaluate the presence of recessive mutations, variant filtering was essentially 
performed as described above, with the main difference being that uniquely 
inherited parental variants were not excluded here. The remaining variants were 
evaluated for the presence of compound heterozygous variants, as well as variants 
that were present in >80% of all reads. Subsequently, parental exome data were 
used for segregation analysis of the variants identified.
DBSNP AND HGMD
To explore the pathogenicity of our de novo variants, the genomic evolutionary 
conservation score (phyloP) and the amino-acid change (Grantham) were compared 
to those scores present in dbSNP (build 130) and the HGMD (see URLs). All non-
synonymous changes reported in dbSNP and HGMD were retrieved, and overlap 
between databases was removed from both datasets. In addition, non-synonymous 
variants in dbSNP with an OMIM disease entry, suggestive for a Mendelian 
phenotype, were omitted from the dbSNP dataset.
Next, quadratic discriminant analysis [30] was performed on these two datasets to 
determine the significance of the phyloP and Grantham scores as discriminating 
factors. Statistical tests were performed using the R statistics package (see URLs). 
The assumption of normality in the data required for the model was determined 
using Lilliefors (Kolmogorov-Smirnov) normality testing [31]: PhyloP D=0.0626, 
P<2.2 × 10−16; Grantham D=0.0828, P<2.2 × 10−16; PhyloP × Grantham D=0.1395, 
P<2.2 × 10−16. D represents the maximum absolute difference between the empirical 
and hypothetical cumulative distribution function.
The combination of both scores together yielded the highest power to discriminate 
the two datasets, and as such, the combined value was used to calculate probabilities 
for our de novo variants to be observed in either database.
VALIDATION EXPERIMENTS
Validation and de novo testing for candidate de novo mutations was performed 
using standard Sanger sequencing approaches. Primers were designed to surround 
the candidate mutation, and PCR reactions were performed using RedTaq Readymix 
PCR reaction mix (Sigma-Aldrich). Primer sequences and PCR conditions are available 
upon request. For all de novo mutations identified, an additional control cohort of 
75 ethnically matched controls was tested for the presence of the same mutation 
by Sanger sequencing. Together with the results from 679 control individuals from 
the 1000 Genomes Project as well as the 78 ‘exomes’ present in our in-house 
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database, the control cohort for the de novo mutations encompassed 1,664 control 
chromosomes.
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ABSTRACT
BACKGROUND
The causes of intellectual disability remain largely unknown because of extensive 
clinical and genetic heterogeneity.
METHODS
We evaluated patients with intellectual disability to exclude known causes of the 
disorder. We then sequenced the coding regions of more than 21,000 genes obtained 
from 100 patients with an IQ below 50 and their unaffected parents. A data-analysis 
procedure was developed to identify and classify de novo, autosomal recessive, and 
X-linked mutations. In addition, we used high-throughput resequencing to confirm 
new candidate genes in 765 persons with intellectual disability (a confirmation 
series). All mutations were evaluated by molecular geneticists and clinicians in the 
context of the patients’ clinical presentation.
RESULTS
We identified 79 de novo mutations in 53 of 100 patients. A total of 10 de novo 
mutations and 3 X-linked (maternally inherited) mutations that had been 
previously predicted to compromise the function of known intellectual-disability 
genes were found in 13 patients. Potentially causative de novo mutations in novel 
candidate genes were detected in 22 patients. Additional de novo mutations in 3 
of these candidate genes were identified in patients with similar phenotypes in the 
confirmation series, providing support for mutations in these genes as the cause 
of intellectual disability. We detected no causative autosomal recessive inherited 
mutations in the discovery series. Thus, the total diagnostic yield was 16%, mostly 
involving de novo mutations.
CONCLUSIONS
De novo mutations represent an important cause of intellectual disability; exome 
sequencing was used as an effective diagnostic strategy for their detection. (Funded 
by the European Union and others.)
INTRODUCTION
Severe intellectual disability, which is also referred to as cognitive impairment 
or mental retardation, affects approximately 0.5% of the population in Western 
countries [1,2] and represents an important health burden. A clinical diagnosis 
of severe intellectual disability is generally based on an IQ of less than 50 and 
substantial limitations in activities of daily living. In early childhood, the diagnosis is 
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based on substantial developmental delays, including motor, cognitive, and speech 
delays. Children with different nonsyndromic forms of intellectual disability are 
clinically indistinguishable.
Intellectual disability can be caused by nongenetic factors, such as infections 
and perinatal asphyxia. In developed countries, most severe forms of intellectual 
disability are thought to have a genetic cause [2], but the cause remains elusive in 
55 to 60% of patients [3,4]. An understanding of the genetic cause of intellectual 
disability can benefit patients and their families, because a diagnosis may provide 
information on the prognosis, precludes further unnecessary invasive testing, and 
may lead to appropriate therapy. Moreover, a diagnosis often facilitates access to 
appropriate medical and supportive care [5-8]. Family members may benefit from 
knowledge of the risk of recurrence, reproductive counseling, and possible prenatal 
diagnosis.
We [9] and others [10] have reported evidence supporting the hypothesis that 
rare de novo point mutations can be a major cause of severe intellectual disability. 
Recent studies have indicated that there are more de novo mutations in persons with 
intellectual disability than in healthy controls, highlighting the clinical importance 
of these mutations [11-15]. That intellectual disability is often sporadic, without 
obvious environmental or familial factors, provides additional support for the 
hypothesis that a large proportion of cases of intellectual disability are caused by de 
novo mutations. It has been estimated that mutations in more than 1000 different 
genes may cause intellectual disability [16]. Because of this large aggregate target, 
rare de novo mutations in these genes may collectively compensate for the very 
low rate of reproduction among patients with intellectual disability, keeping the 
incidence of the disorder in the general population stable [15]. 
In the absence of diagnostic clues from the clinical phenotype, unbiased genome-
wide approaches are required to detect genetic mutations causing intellectual 
disability [9,17,18]. We have therefore evaluated the role of de novo as well as 
X-linked and autosomal recessive inherited mutations in a series of 100 patients 
with unexplained intellectual disability defined as an IQ of <50), using a family-
based exome-sequencing approach in a clinical diagnostic setting. Previous 
extensive clinical and genetic evaluation of these patients had not led to an etiologic 
diagnosis. Thus, this series of patients represents the end point of current diagnostic 
strategies, with all conventional genetic resources exhausted, which is the typical 
scenario for patients with severe intellectual disability [19].
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Table 1, Clinical characteristics of 100 patients with Intellectual Disability of unknown cause.
Characteristic No. of Patients Characteristic No. of Patients
IQ Short stature
<30 62 Yes 24
30 to 50 38 No 76
Gender Microcephaly
Male 47 Yes 30
Female 53 No 70
Age group Macrocephaly
<10 yr 37 37 Yes 4
10–20 yr 41 No 96
>20 yr 22 Epilepsy
No. of siblings Yes 52
0 12 No 48
1 47 Abnormality on brain imaging
2 36 Yes 30
3 1 No 40
4 2 Not assessed 30
Unknown 2 Cardiac malformation
No. of major congenital anomalies Yes 2
0 62 No 98
1 31 Abnormality of the urogenitary system
2 7 Yes 13
3 0 No 87
No 48
METHODS
PATIENTS
We enrolled 100 patients (53 females and 47 males) with unexplained severe 
intellectual disability and their unaffected parents (trios). This series is broadly 
representative of patients with severe intellectual disability who are referred to our 
tertiary care clinic (see Table S1). All patients were evaluated by a clinical geneticist. 
Detailed clinical phenotypes of the 100 patients are provided in the section on the 
clinical descriptions of patients in the Online Supplementary Appendix and are 
summarized in Table 1. Before enrollment, the patients had undergone an extensive 
diagnostic workup, including genomic profiling (performed with the use of the 250K 
Affymetrix SNP array) and targeted gene tests, with metabolic screening whenever 
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indicated, but these evaluations had not led to an etiologic diagnosis. The study was 
approved by the ethics committee at the Radboud University Nijmegen Medical 
Center. The parents of all patients in the study provided written informed consent.
DETECTION OF MUTATIONS
Genomic DNA was isolated from blood with the use of a QIAamp DNA Mini Kit 
(Qiagen). Exomes were enriched with the use of a SOLiD-Optimized SureSelect 
Human Exome Kit (Agilent version 2, 50 Mb), followed by SOLiD 4 System sequencing 
(Life Technologies). After sequencing the exomes of each trio, we selected candidate 
de novo mutations by excluding variants inherited from either parent and selected 
candidate recessive and X-linked mutations by segregation analysis (Figure S1 in 
the Supplementary Appendix). Candidate de novo mutations were validated by 
conventional Sanger sequencing methods in DNA samples obtained from the 
patients and their parents (see the section on validation of de novo mutations in 
the Supplementary Appendix).
TESTING OF CANDIDATE GENES
We reanalyzed all candidate genes that were identified in this study for the presence 
of possible de novo mutations in previously generated exome data obtained from 
10 patients with severe intellectual disability [9]. In addition, we resequenced five 
candidate genes associated with intellectual disability (DYNC1H1, KIF5C, ASH1L, 
GATAD2B, and CTNNB1) using array-based enrichment on pooled DNA samples 
from a second series of 765 patients with intellectual disability. These samples 
were selected from our in-house collection of 5,621 samples from patients with 
undiagnosed intellectual disability (see the section on patient selection in the 
Supplementary Appendix). The parents of these patients had previously provided 
written informed consent. All patients had been evaluated by a clinical geneticist 
to rule out known causes of intellectual disability, and genomic array analysis had 
not revealed causal copy-number variants. Detected variants were annotated and 
prioritized according to their presumed relevance to disease. Variants fulfilling 
prioritization criteria were validated by means of conventional Sanger sequencing 
(see the section on recurrence screening in the Supplementary Appendix).
INTERPRETATION OF CONFIRMED MUTATIONS
We classified the mutations on the basis of the existing guidelines for evaluation 
of the pathogenicity of variants [20,21] (Figure 1, and the section on clinical 
interpretation of mutations in the Supplementary Appendix). These guidelines call 
for the evaluation of seven factors: the function of the affected gene, the effect of 
the mutation on the codon (i.e., stop, frameshift, or missense mutation), in silico 
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Figure 1. Classification of Variants Detected in Patients with Severe Intellectual Disability 
(ID). Variants in known autosomal recessive (AR) genes were considered to be diagnostically 
relevant only if biallelic, predicted pathogenic variants were detected. AD denotes autoso-
mal dominant, and XL X-linked.
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prediction of the functional effect at the amino acid level, evolutionary conservation, 
brain-expression patterns, analysis of gene ontology (GO) terms, and the use of 
animal models, if available (see the section on mutational effect and functional 
relevance in the Supplementary Appendix). 
Mutations in genes with a known association with intellectual disability were 
considered to be a cause of intellectual disability when the mutations were 
predicted to be pathogenic by the majority of three prespecified in silico analyses 
(see the section on mutational effect in the Supplementary Appendix) and when 
they occurred in persons with phenotypes similar to those described in other 
persons with mutations in these genes.
Mutations were considered to affect candidate genes that had not previously 
been implicated in intellectual disability when the mutations were predicted to 
be pathogenic by the majority of three prespecified in silico analyses, showed a 
link to brain or embryonic development in a review of the literature, and met at 
least two of the following criteria: evolutionary conservation, brain-expression 
pattern, positive results on GO term analysis, or implication on the basis of animal 
models (see the section on functional relevance in the Supplementary Appendix). If 
multiple patients were found to have a de novo mutation in such a candidate gene 
and their phenotypes showed striking overlap, the candidate gene was redefined 
as a novel intellectual disability gene, and the mutations were reported as a cause 
of intellectual disability. All mutations in other candidate genes were reported as a 
possible cause of intellectual disability. For patients without causal de novo, X-linked, 
or biallelic inherited mutations, the diagnostic report stated that the genetic cause 
of intellectual disability was not identified.
RESULTS
EXOME SEQUENCING
The power of family-based exome sequencing to provide a genetic diagnosis was 
evaluated for 100 patients with unexplained intellectual disability. The median 
sequence coverage was 64, with an average of 87% of all targeted exons covered by 
at least 10 sequence reads (Table S1 & Figure S2 in the Supplementary Appendix). 
We detected an average of 24,324 genetic variants per patient (Table S2 in the 
Supplementary Appendix). An automated prioritization scheme was applied to 
systematically identify candidate de novo mutations (Figure S1 in the Supplementary 
Appendix), resulting in a total of 690 candidate de novo mutations (average number 
per patient, 7; range, 2 to 20) (Table S2 in the Supplementary Appendix). 
An inherent challenge in family-based exome sequencing is the difficulty in 
distinguishing between a true de novo mutation and a sequencing error, since 
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both appear to be a new allele in the patient. Therefore, we tested the veracity 
of all candidate de novo mutations using Sanger sequencing as an independent 
method and confirmed the presence of 79 de novo mutations in 53 patients (range 
per patient, 1 to 4) (Tables S3 and S4 & Figure S3 and S4 in the Supplementary 
Appendix).
DESCRIPTION OF DE NOVO MUTATIONS
Of the 79 de novo mutations (affecting 77 genes), 16 were synonymous (Figure 1). Of 
these mutations, none were predicted to alter splicing. Therefore, these mutations 
were classified as not causative for intellectual disability. The remaining 63 changes 
were nonsynonymous and included 15 mutations that were predicted to be 
severely disruptive (4 nonsense mutations, 2 canonical splice-site mutations, and 9 
insertions or deletions) and 48 missense mutations (Table S3 in the Supplementary 
Appendix). On the basis of random mutation modeling, 22 our observation of 4 
nonsense mutations (6.1%) exceeded expectations (3.3%) and thus supports an 
elevated level of such mutations in patients with intellectual disability (Table S5 in 
the Supplementary Appendix). Prediction of all 48 missense mutations with the use 
of Polymorphism Phenotyping, version 2 (PolyPhen2), showed a significant increase 
in mutations that were probably damaging (p=0.03) (Table S5 in the Supplementary 
Appendix). This finding suggested that a large portion of these missense mutations 
might have phenotypic consequences.
We detected 12 de novo mutations in known intellectual-disability genes: 6 
severely disruptive mutations and 6 missense mutations (Table 2 & Table S3 in the 
Supplementary Appendix). Three de novo mutations were detected in genes known 
to cause a recessive form of intellectual disability when mutated. These mutations 
would be considered causal for intellectual disability only if a second, inherited 
mutation that was predicted to be pathogenic was identified. We identified no such 
mutation in ARFGEF2 or TUSC3. However, we did detect a rare paternally inherited, 
predicted pathogenic variant (c.6160G>A; p.(Asp2054Asn)) in LRP2. The results 
of analyses performed to determine whether the de novo event occurred on the 
maternal haplotype were inconclusive. Recessive LRP2 mutations cause the Donnai–
Barrow syndrome, and clinical reevaluation of Patient 81 confirmed this diagnosis 
(Table S6 and the Clinical Description of Patients section in the Supplementary 
Appendix).
We analyzed the remaining 51 de novo mutations and identified 25 mutations in 24 
candidate genes (Table S3 in and the Supplementary Appendix). A patient with a de 
novo DYNC1H1 mutation and intellectual disability has been described previously 
[9]. A comparison between that patient and Patient 54 in our study showed that 
they both had severe intellectual disability and a variable presentation of a neuronal 
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migration defect [23] (Figure S5 in the Supplementary Appendix).
ADDITIONAL PATIENTS WITH INTELLECTUAL DISABILITY
We reanalyzed previously generated exome data for 10 patients with undiagnosed 
severe intellectual disability [9] and resequenced five candidate genes associated 
with intellectual disability (DYNC1H1, GATAD2B, ASH1L, KIF5C, and CTNNB1) in a 
series of 765 persons with intellectual disability in order to identify additional de 
novo mutations (Tables S7 and S8 in the Supplementary Appendix). 
In this confirmation series, we identified a second de novo mutation in the 
transcriptional repressor GATAD2B. The two de novo mutations that were observed 
in this gene, a nonsense p.(Gln470*) and a frameshift p.(Asn195Lysfs*30) mutation, 
both resulting in a stop codon (indicated by the star symbol), were predicted to be 
severely disruptive and to result in loss of function (Figure S6 in the Supplementary 
Appendix). Both patients with these mutations presented with severe cognitive and 
motor delays and limited speech, and the two patients had similar facial features. 
One additional severely disruptive de novo mutation was detected in CTNNB1 (Figure 
S7 in the Supplementary Appendix). This mutation (p.(Arg515*)) and the de novo 
mutation detected on exome sequencing (p.(Ser425Thrfs*11)) were predicted to 
result in loss of function. A third patient carried a p.(Gln309*) mutation in CTNNB1. 
This mutation was not present in maternal DNA, and paternal DNA was unavailable. 
All three patients presented with severe intellectual disability, absent or very limited 
speech, microcephaly, and spasticity with a severely impaired ability to walk.
Patients 4 and 15 had de novo missense mutations in TRIO: p.(Asp1368Val) and 
p.(Thr2563Met), respectively. TRIO encodes a protein that acts in several signaling 
pathways that control cell proliferation [24]. These patients were not similar in 
any clinical respect other than intellectual disability (see the section on clinical 
descriptions in the Supplementary Appendix). Both patients also carried a mutation 
in a known intellectual-disability gene: PDHA1 in Patient 4 and TCF4 in Patient 15. 
Their phenotypes overlapped markedly with those of other patients with mutations 
in PDHA1 and TCF4 (Table S6 in the Supplementary Appendix), indicating that these 
mutations are the most likely cause of intellectual disability, although the mutations 
in TRIO may also play a part.
INHERITED MUTATIONS IN AUTOSOMAL RECESSIVE AND X-LINKED GENES
We detected 14 X-linked inherited mutations in 12 male patients (Table S9 in the 
Supplementary Appendix). Three of these mutations were located in known X-linked 
intellectual-disability genes (one in PDHA1 and two in ARHGEF9). These mutations 
were predicted to be pathogenic, and the phenotypes that were observed in 
the patients were consistent with previous reports of affected persons carrying 
60
mutations in these genes (Table S6 in the Supplementary Appendix). In 10 male 
patients, we also detected 11 X-linked inherited mutations in 11 genes that had 
not previously been associated with intellectual disability. Of these genes, TRPC5 
was classified as possibly causal. The analysis for autosomal recessive causes of 
intellectual disability revealed biallelic inherited mutations in 9 genes, including 2 
genes (PCNT and VPS13B) that had previously been associated with an autosomal 
recessive form of intellectual disability. None of these mutations had been classified 
as a possible cause of intellectual disability (Table S9 in the Supplementary 
Appendix).
Table 2, Genes Affected by De Novo Mutations Associated with Intellectual Disability.
Type of 
mutation
Known 
genes
Novel 
genes* Candidate genes
Missense
ARFGEF2 †, 
GRIN2A ‡, 
GRIN2B, TCF4, 
TUSC3 †
DYNC1H1
ASH1L, CAMKIIG, COL4A3BP, EEF1A2, 
GRIA1, KIF5C, LRP1, MIB1, PHACTR1, 
PPP2R5D, PROX2, PSMA7, RAPGEF1, 
TANC2, TNPO2, TRIO ‡
Nonsense SCN2A GATAD2B PHIP, WAC
Frameshift
LRP2 §, PDHA1 
SLC6A8, TUBA1A
CTNNB1 MTF1, ZMYM6
Splice site SYNGAP1 MYT1L
* Genes were defined as novel if there were additional de novo mutations in patients 
with phenotypic overlap. Details on de novo mutations are provided in Table S3 in the 
Supplementary Appendix.
† This autosomal recessive gene was identified as mutated in a patient in whom no second 
mutation was detected.
‡ De novo mutations in this gene were found in two independent patients.
§ This autosomal recessive gene was found in a patient in whom a second rare, inherited 
mutation was detected.
FAMILY-BASED EXOME SEQUENCING
Conclusive genetic diagnoses were obtained for 10 patients with de novo mutations 
in known intellectual-disability genes and for 3 male patients with severely 
disruptive, maternally inherited mutations in known X-linked intellectual disability 
genes (Tables S3 and S9 in the Supplementary Appendix). The phenotypes of these 
patients fit well with previously reported phenotypes caused by mutations in these 
genes (Table S6 and the section on clinical descriptions in the Supplementary 
Appendix). No diagnostically relevant, inherited autosomal recessive mutations 
were identified. Thus, a diagnostic yield of 13% was obtained from mutations in 
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known intellectual-disability genes (Table S10 in the Supplementary Appendix).
Our study identified 24 novel candidate genes affected by de novo mutations. A 
pathogenic role for 3 of these genes was substantiated by the identification of 
additional patients with intellectual disability and severely disruptive mutations. In 
each case, there was striking phenotypic overlap observed among the patients with 
mutations in the same gene. We therefore conclude that DYNC1H1, GATAD2B, and 
CTNNB1 are novel intellectual disability genes, which raises the diagnostic yield of 
exome sequencing to 16% (Table 2 and 3).
Table 3. Diagnostic Yield of Exome Sequencing in the Patients.
Positive Diagnosis No. of Patients
All mutations 16
De novo mutations 13
Autosomal dominant   10*
X-linked 2
Autosomal recessive   1†
Inherited mutations 3
X-linked 3
Autosomal recessive 0
* Seven patients had mutations in autosomal dominant genes that had previously been 
associated with intellectual disability, and three patients had mutations in novel autosomal 
dominant genes.
† This patient had one de novo mutation and a second inherited, predicted pathogenic 
mutation.
DISCUSSION
Mutations in more than 400 genes have been linked to intellectual disability, but 
most of these mutations have a very low prevalence and their phenotypes are often 
indistinguishable. This argues for an unbiased diagnostic approach, especially since 
these 400 genes may represent less than half of all intellectual-disability genes. We 
implemented family-based diagnostic exome sequencing for patients with severe, 
unexplained intellectual disability. Exome sequencing is a procedure that is highly 
amenable to automation. Variants with potential clinical consequences can easily 
be validated with the use of Sanger sequencing as an independent method. We 
did not identify any major hurdles in the laboratory workflow in this study, which 
allowed for smooth integration of this process into diagnostics. De novo mutations 
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were present in 53% of the patients and provided a conclusive genetic diagnosis 
in at least 13%, with an additional 3% of X-linked inherited mutations in known 
intellectual-disability genes. This diagnostic yield is similar to that of current 
chromosomal analyses based on genomic arrays, and the two approaches are 
complementary [4,25-27]. We expect that the diagnostic rate of exome sequencing 
will increase with the identification of additional patients who have mutations in 
the novel candidate genes reported here.
The identification of causal mutations in known intellectual-disability genes in 16 
of 100 patients provides clinically useful information for clinicians and for patients 
and their families, since much is known about the prognoses associated with 
these mutations. The identification of the underlying genetic cause may also lead 
to specific treatment options or dietary advice. As an example, a ketogenic diet 
was recommended for our patients with a mutation in PDHA1 [28]. In addition, a 
specific anti-epileptic treatment, with the avoidance of sodium-channel blockers, 
was suggested for our patient with a de novo SCN2A mutation, since this therapy 
leads to better seizure control and improvement in cognitive functioning and quality 
of life in patients with SCN1A mutations [29].
Our studies suggest that several of the new candidate genes that we identified may 
be confirmed as having recurrent mutations in patients with intellectual disability. 
We already identified additional de novo mutations in three of five genes (DYNC1H1, 
GATAD2B, and CTNNB1) that were sequenced in a second set of affected persons, 
and detailed clinical analysis of these patients provided definitive evidence that 
these three genes cause intellectual disability when mutated. The identification of 
recurrently mutated genes in combination with detailed clinical phenotyping may 
reveal novel intellectual-disability genes and identify clinical subtypes of intellectual 
disability that may require specific approaches to clinical management. We observed 
evidence of autosomal recessive disease in only one affected patient, who carried 
a de novo mutation and a rare inherited mutation in LRP2. The apparent absence 
of pathogenic mutations in autosomal recessive intellectual-disability genes in our 
series suggests that this form of intellectual disability is rare in patients with isolated 
intellectual disability from nonconsanguineous parents. An analysis of referrals for 
intellectual disability to our tertiary care center showed that approximately 90% 
of patients have sporadic intellectual disability and nonconsanguineous parents 
(see the Supplementary Appendix). X-linked forms of intellectual disability were 
diagnosed in 5 of 100 patients, and in 2 of these 5 patients, the mutation occurred 
de novo. Mutations outside the coding regions, as well as mosaic, digenic, or 
oligogenic causes of intellectual disability, remain to be defined.
Unbiased diagnostic approaches such as exome sequencing may also reveal 
clinically relevant mutations that are not related to the disease under investigation. 
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An independent expert panel determined the clinical relevance of such incidental 
findings. Before study enrollment, all families were counseled about this possibility 
and consented to being informed if the findings were deemed to be relevant by 
this panel. No families objected to being informed about incidental findings. In this 
study, we encountered one incidental finding, a de novo c.517C>T (p.(Tyr173His)) 
change in RB1. Mutations in this gene are associated with retinoblastoma (Online 
Mendelian Inheritance in Man [OMIM] number, 180200), an embryonic malignant 
neoplasm of retinal origin that is associated with a low risk of osteosarcoma [30]. The 
expert panel considered the risk of retinoblastoma to be negligible for this patient, 
since he had reached the age of 8 years, but decided that it was important to inform 
the parents of the small chance that a sudden, painful swelling of the limbs could be 
caused by an osteosarcoma and that they should consult an oncologist at the first 
sign of such swelling. No further incidental findings were encountered.
In conclusion, our study shows that exome sequencing can be used as a diagnostic 
procedure for patients with severe intellectual disability of unknown cause. The 
diagnostic yield, which was 16% in our series, may increase with improvement in 
methods and the identification of additional genes associated with intellectual 
disability.
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ABSTRACT
Copy number variation (CNV) is a common source of genetic variation that has 
been implicated in many genomic disorders. This has resulted in the widespread 
application of genomic microarrays as a first-tier diagnostic tool for CNV detection. 
More recently, whole-exome sequencing (WES) has been proven successful for the 
detection of clinically relevant point mutations and small insertion-deletions exome 
wide. We evaluate the utility of short-read WES (SOLiD 5500xl) to detect clinically 
relevant CNVs in DNA from 10 patients with intellectual disability and compare 
these results to data from two independent high-resolution microarrays. Eleven 
of the 12 clinically relevant CNVs were detected via read-depth analysis of WES 
data; a heterozygous single-exon deletion remained undetected by all algorithms 
evaluated. Although the detection power of WES for small CNVs currently does not 
match that of high-resolution microarray platforms, we show that the majority (88%) 
of rare coding CNVs containing three or more exons are successfully identified by 
WES. These results show that the CNV detection resolution of WES is comparable to 
that of medium-resolution genomic microarrays commonly used as clinical assays. 
The combined detection of point mutations, indels, and CNVs makes WES a very 
attractive first-tier diagnostic test for genetically heterogeneous disorders.
INTRODUCTION
Whole-exome sequencing (WES) has revolutionized Mendelian disease gene 
identification by providing a powerful tool for exome-wide detection of single-
nucleotide variants (SNVs) and small insertions and deletions (InDels) [Bainbridge 
et al., 2013; Bamshad et al., 2011; Gilissen et al., 2012; Hanchard et al., 2013; Ng et 
al., 2010; O’Roak et al., 2012]. In addition, WES is being introduced as a diagnostic 
procedure for genetically heterogeneous diseases in a number of laboratories [de 
Ligt et al., 2012; Hanchard et al., 2013; Rauch et al., 2012]. Structural variation such 
as copy number variants (CNVs), also contributes to these disorders [Cooper et al., 
2011; Lupski, 2009; Stankiewicz and Lupski, 2010], and is currently not routinely 
assessed from WES data. The identification of CNVs, in addition to SNVs and InDels, 
would increase the versatility of WES as a genome-wide variant detection method 
in research and diagnostics. It would reduce the number of genomic assays required 
per patient to reach a diagnosis and create new possibilities to analyze the combined 
effects of SNVs and structural variation within an individual [Kurotaki et al., 2005].
Genomic microarray platforms based on either single-nucleotide polymorphisms 
(SNPs) or comparative genomic hybridization (CGH) have proven highly successful 
as a robust, high-throughput method for CNV detection [Boone et al., 2010; Pinkel 
et al., 1998; Schaaf et al., 2011; Vissers et al., 2003]. Advances in technology have 
resulted in an increase in the number of probes being included on a single array 
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from hundred thousands of probes (medium resolution) to millions of probes 
(high resolution), resulting in both increased detection power and accuracy. The 
implication of CNVs in a wide range of congenital disorders including intellectual 
disability (ID) and developmental delay, as well as later onset common diseases 
such as schizophrenia and autism, has resulted in the widespread application 
of genomic microarrays as a first-tier diagnostic tool [Lupski, 2012; Mefford and 
Eichler, 2009; Miller et al., 2010; Vissers et al., 2010]. The resolution to detect CNVs 
using genomic microarrays is strongly governed by the spacing and number of 
interrogating oligonucleotide probes, and the microarray design [Boone et al., 2010; 
Hehir-Kwa et al., 2007; Pinto et al., 2011]. However, intragenic CNVs remain beyond 
the detection limit of most clinical genomic microarray analysis, with the exception 
of custom microarray designs with enhanced exonic coverage for selected disease 
genes [Boone et al., 2010].
In contrast to most available genome-wide microarrays, WES specifically targets 
exonic regions and is mostly blinded to the remainder of the genome. The most 
widely applied massively parallel sequencing technologies sequence short reads 
(50-125 bp), either as fragments or as paired ends [Bamshad et al., 2011]. The 
most commonly applied methods for CNV detection in WES data are based on 
the analysis of the read depth, utilizing the number of fragments mapping within 
a genomic region as a measure of the amount of DNA present at the locus. This 
measure is used to determine a ratio between a test sample and reference samples 
[Haraksingh et al., 2011; Klambauer et al., 2012; Krummet al., 2012; Plagnol et al., 
2012], and results in an estimation of copy number for a given genomic segment, 
similar to what is used for array based platforms. Read count data can, however, 
be distorted by the capture procedure used to isolate the coding portions of the 
genome and by inaccurate alignment of sequencing reads to the reference genome. 
For example, it is well documented that the percentage of Guanine and Cytosine 
nucleotides in the region significantly influences the binding affinity during capture 
and sequencing [Metzker, 2010]. In addition, the presence of low copy repeats can 
negatively influence alignment of sequence reads to the reference genome and 
thereby distort copy number estimations of a region [Teo et al., 2012].
To date, CNV detection in next generation sequencing data has been largely limited 
to sporadic cases and healthy control populations in a research setting [Mills et al., 
2011]. Here, we evaluate the detection of clinically relevant, rare de novo CNVs 
of varying size and copy number state via WES. We compare the performance of 
WES for CNV detection with that of both commercially available as well as custom 
designed, high-resolution array CGH enhanced for coding regions using up to 4.2 
million interrogating oligonucleotides.
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MATERIALS AND METHODS
SAMPLE SELECTION
Ten samples were selected that had previously been diagnostically reported as 
containing at least one clinically relevant, rare de novo CNV associated with ID, 
detected by routine microarray based screening within the Department of Human 
Genetics, Radboud University Medical Centre, Nijmegen. These CNVs were chosen 
to represent a wide range of clinically relevant CNVs detected by microarray based 
analysis in our Genome Diagnostics division. The selected CNVs (1) contained at least 
one coding region, (2) were validated de novo using the same microarray platform 
on parental DNAs, (3) occurred across a variety of chromosomes, (4) ranged in copy 
number state from zero to three, and (5) ranged in genomic size from 15 kb to 24 
Mb (Table 1). Eleven of these de novo CNVs were detected using an Affymetrix 
250k NspI (Affymetrix, Santa Clara, CA) microarray and one, in patient 1, with the 
Affymetrix 2.7M microarray platform (Table 1).
WES AND CNV DETECTION
WES was performed as described by de Ligt et al. (2012); in brief, genomic DNA from 
these 10 samples was isolated from blood using the QIAamp DNA Mini Kit (Qiagen, 
Venlo, The Netherlands). Exomes were enriched using a SOLiD-Optimized Agilent 
SureSelect Human Exome Kit, V2 (Agilent Technologies, Santa Clara, CA), followed 
by SOLiD sequencing using a 5500xl System (Life Technologies, Carlsbad, CA) to a 
median read depth of 67 across targeted regions. Read correction and mapping 
were performed with Lifescope v1.3 (Life Technologies), using default settings. The 
WES data were analyzed with four different published CNV detection programs; (1) 
cn.MOPS v1.6.4 [Klambauer et al., 2012], (2) CONTRA v2.0.3 [Li et al., 2012], (3) 
CoNIFER v0.2.0 [Krumm et al., 2012], and (4) ExomeDepth v0.8.4 [Plagnol et al., 
2012] (see Supplementary Methods), with unique hg19-based RefSeq gene exon 
definitions as target regions in the analysis.
ADDITIONAL GENOMIC MICROARRAY STUDIES
All samples were also analyzed on two independent, microarray platforms: (1) a 
high-resolution SNP microarray (Affymetrix CytoScanHD with 2.6 million probes; 
“CytoScanHD”) (Affymetrix) and (2) a high-density CGH microarray enhanced for 
exonic regions (NimbleGen 4.2 million probe custom design; “ExonArray”) (Roche 
NimbleGen, Madison, WI). Detailed experimental methods and computational 
approaches/software parameters are described in the Supplementary Methods.
The aim of the ExonArray design was to cover each exon (Supplementary Methods), 
and flanking sequence, with at least eight oligonucleotide probes. After testing and 
optimization (see Supplementary Methods), the ideal coverage of eight or more 
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probes was achieved for over 135,000 (~86%) exons; 249 (0.16%) of the exons could 
not be targeted at all. To test the sensitivity of the ExonArray, seven DNAs with 
10 previously described CNVs (nine deletions and one duplication) with a median 
size of 8.5 kb (size range 1.6 kb-1.7 Mb) [Boone et al., 2013; Zhang et al., 2009] 
were analyzed (Supplementary Figure S1). NimbleGen performed the microarray 
experiments in a blinded fashion using mixed control DNAs. All the 10 CNVs were 
identified successfully indicating 100% sensitivity for these events, which were as 
small as 1.6 kb, five being smaller than 10 kb, and of which four encompassed only 
a single exon (Supplementary Figure S1).
CNV ANNOTATION
Prior to annotation and interpretation, CNV calls resulting from both the WES 
approach and the ExonArray were subject to additional merging (Supplementary 
Methods). To facilitate interpretation, we annotated all CNVs for their gene content, 
(UCSC hg19 track GeneSymbols), the total number of genes, and the number of 
unique coding exons within the region. Since mapping artifacts can lead to false 
positive (FP) signals in sequencing data, the CNVs were annotated for features 
related to the uniqueness of the genomic region, the repeat content (simple and 
complex), and the percentage of SelfChain alignment in the region, based on the 
UCSC repeat tracks.
A reference set was generated to represent common CNV regions detected by the 
different platforms (both high-resolution microarrays and WES) and algorithms 
used in this study to determine which genomic regions were copy number variable 
(common CNVs). The reference set contained all events observed in more than one 
individual, by any specific platform in this study, as well as CNVs identified in our 
in-house set of control samples. This in-house dataset contains CNVs identified in 
1,200 healthy individuals analyzed with the Affymetrix 6.0 SNP microarray platform 
[Franke et al., 2010] and 650 individuals analyzed with the Affymetrix CytoScanHD. 
The combined dataset included in total 23,125 gains and 56,066 losses.
OVERALL CNV DETECTION POWER OF WES
The false negative (FN) detection rate of WES was calculated by measuring the 
number of CNV events detected using the high resolution microarray platforms 
that were missed by WES. To prevent overestimation due to platform design 
(exon targeted vs. whole genome), we accounted for both the exome enrichment 
targets and the detection power of WES. We selected CNVs that were identified 
by at least two independent microarray platforms (minimum overlap of 30% of 
the CNV region, to allow for breakpoint inaccuracies due to the large differences 
in probe densities) and the CNV had to encompass at least three exons. For each 
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CNV, the largest region, detected by the CytoScanHD or the ExonArray, was used 
for further analysis. After applying these selection criteria to the total set of 6,074 
CNV identified by the different microarray experiments, the resulting consensus 
dataset contained 97 CNVs. Of these 97 consensus CNVs, 25 did not occur in the 
common CNV dataset and were considered rare CNVs. Consensus CNVs were only 
considered as positively detected by WES if a CNV was called in the same region and 
overlapped the consensus CNV region for at least 30%.
BREAKPOINT ANALYSIS
To study the differences in detected CNV breakpoints across detection platforms, an 
overlap analysis was performed on the 11 clinically relevant CNVs. CNVs overlapping 
the discovery region were merged into a maximum confirmation CNV, and 
breakpoint differences were calculated based on the genomic coordinates of the 
two CNVs. The difference in genomic location was measured for each breakpoint by 
subtracting the genomic location as defined by the high-resolution array consensus 
from the location identified by the confirmation platform.
DATA AVAILABILITY
CNVs identified in this study by the different platforms have been submitted to dbVar 
under nstd84; sample identifiers correspond to those used in this paper. Detailed 
information on clinical presentation and the pathogenic event is available through 
ECARUCA for all patients under the following accession numbers (patient 1-10): 
5042, 5045, 4785, 5044, 4545, 4487, 4581, 5043, 4452, and 4685, respectively. Raw 
data of the discovery microarray experiments are available in the Gene Expression 
Omnibus (GSE46060); sample identifiers correspond to those used in this paper.
RESULTS
Our study aimed to investigate the diagnostic potential of CNV identification from 
short-read WES (SOLiD 5500xl) data. For this, we selected a set of 12 clinically 
relevant and validated, rare de novo CNVs detected using either an Affymetrix 
250k NspI or 2.7M microarray, in 10 individuals with ID. This set of CNVs varied in 
genomic size and copy number state and incorporated both autosomal and X-linked 
CNVs (Table 1). WES was performed on all 10 samples and CNVs were called using 
four published CNV detection algorithms. In addition, high-resolution microarray 
experiments were performed using two independent platforms to experimentally 
assess the genome-wide true positive (TP), FP, and FN CNV detection rates of WES.
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Figure 1. Detection of clinically relevant CNVs by WES. Black circles represent test over refer-
ence ratio values generated from WES data using CoNIFER; singular value decomposition 
(SVD) and Z-score adjusted read count per million (ZRPKM). Gray boxes indicate RefSeq gene 
exons; boxes above the ratio values represent CNV gains and below CNV deletions. A: A 1.1 
Mb deletion including 24 genes. B: A 720 kb duplication including 17 genes. C: A 23 kb dele-
tion containing two genes.
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DETECTION OF THE CLINICALLY RELEVANT CNVS
The four different WES CNV identification algorithms varied in their ability to 
correctly identify the 12 clinically relevant CNVs (Table 1). ExomeDepth and CoNIFER 
performed best, correctly identifying 10 and 11 of the 12 clinically relevant CNVs, 
respectively (Table 1, Figure 1, for examples of WES-based CNV detection using 
CoNIFER). Of note, all WES algorithms failed to detect a clinically relevant single 
exon deletion (15 kb in size) in patient 1, which was originally detected using the 
Affymetrix 2.7M microarray. While CONTRA and cn.MOPS often called a CNV in 
the relevant CNV region, the identified CNV was small and overlapped less than 
30% (cut off threshold used for successful detection) with the interval identified by 
the discovery microarray. The copy number state reported by the WES-based CNV 
algorithms matched the copy number estimated by the microarrays for all CNVs.
GENOME-WIDE CNV DETECTION USING WES
The four different CNV WES detection algorithms varied widely in the total number of 
CNVs detected across the 10 samples; CONTRA identified 1,464 CNVs, ExomeDepth 
1,482 CNVs, cn.MOPS 329 CNVs, and CoNIFER 65 CNVs in total (Supplementary 
Table S1). All but one (99.9%) of the CNV events identified by CONTRA contained 
three or fewer coding exons. Similarly, many CNVs identified by cn.MOPS (56%) 
and ExomeDepth (58%) also contained three or fewer coding exons; in contrast, 
CoNIFER focuses more on detecting larger and rare CNVs, and detected only six (9%) 
such small CNVs (Supplementary Figure S2).
To evaluate the reliability of CNV identification using WES, we compared the results 
to CNVs detected by the different microarray platforms used in this study (Affymetrix 
250k NspI/2.7M, Affymetrix CytoScanHD and the NimbleGen 4.2M ExonArray). In 
total, 38 of the 65 (59%) CNVs identified using CoNIFER were supported by one 
(n=10) or more (n=28) of the microarray platforms (Table 2). The confirmed events 
were larger (median 63.7 kb) and contained more exons (median 21.5) compared 
to the unsupported CNVs (median size 16.3 kb, median number of exons is 7). 
Similarly, 50% of the CNVs identified by cn.MOPS were supported by a microarray 
CNV, whereas a much smaller proportion of CNVs identified by CONTRA (17%) and 
ExomeDepth (16%) was supported by one or more microarray platforms (Table 2).
While genome-wide accuracy measures are an important indication of algorithm 
performance, in a clinical setting, it is important to consider the number of missed 
rare, genic events. To evaluate the FN rate of WES CNV detection, we investigated 
the detection of a CNV consensus set containing 25 rare coding CNVs detected by 
the two highest resolution microarray platforms used (ExonArray and CytoscanHD, 
see Materials and Methods). The overlap analysis showed the best detection rate 
for CoNIFER (88%), missing 3 of the 25 rare, genic events (Table 2). In general, the 
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Figure 2. Detection of clinically relevant CNVs in two patients by the different platforms. 
Black circles are the log2 test over reference ratio values obtained through the different 
microarray experiments and singular value decomposition (SVD) and Z-score adjusted read 
count per million (ZRPKM) values for WES. (legend continues on the next page) 
79
D
etecti
on of clinically relevant CN
Vs w
ith w
hole exom
e sequencing
Chapter 4
Boxes below ratio values represent the CNV deletion as detected by the different platforms; 
gray boxes indicate RefSeq gene exons, and the vertical dotted lines indicate the minimally 
deleted region detected by the discovery microarray.
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CNV events not detected by the WES approach using CoNIFER contained fewer 
exons (3, 4, and 17 exons) than those CNVs that were detected (median 27 exons).
Overall, CoNIFER proved to be the most reliable CNV detection program for 
diagnostic applications based on a number of features: 1) most of the clinically 
relevant CNVs were detected (11 out of 12); 2) the highest percentage of CNVs 
were supported by an independent method (59%); and 3) the lowest number of 
rare consensus CNVs were missed (12%). All of the other algorithms had high FP 
rates and missed large numbers of rare CNVs, as well as the clinically relevant CNVs 
(Tables 1 & 2), making them unsuitable for diagnostic applications. Further analyses 
of WES CNV identification were based on the calls by CoNIFER.
DETERMINING THE ACCURACY OF CNV IDENTIFICATION
The experimental design of WES leads to a nonuniform distribution of data points, 
focused only on the coding regions, whereas most genomic microarrays have a probe 
distribution containing a backbone covering the entire genome. To assess the effect 
of the unequal probe distribution of WES on the accuracy of CNV identification, 
we compared the breakpoints of the 11 clinically relevant CNVs detected across 
all four experimental platforms (discovery microarray, WES, CytoScanHD, and the 
ExonArray).
We generated consensus breakpoints based on the results from the highest 
resolution microarray platforms (CytoScanHD and ExonArray). The breakpoints of 
the WES CNV detection mapped within 200 kb of the consensus breakpoints for 
18 of the 22 breakpoints (Table 3, Figure 2, for example plots of CNV detection on 
different platforms). Three of the four breakpoints, which deviated more than 200 
kb, occurred in regions with a much lower exon density as compared with the well 
mapped breakpoints (mean of 1.83 vs. 59.5 exons within 500 kb of the breakpoint 
region).
PREDICTING THE DIAGNOSTIC YIELD OF CNV IDENTIFICATION USING WES
After determining the power to detect CNVs in WES data, we estimated the impact 
of using WES CNV detection on a larger set of samples within a clinical setting. For 
this, we compiled a list of 470 clinically relevant de novo CNVs detected by diagnostic 
microarray analysis in our center using a combination of Affymetrix 250k NspI, 2.7M 
and CytoScanHD microarray platforms. For each de novo CNV, the number of exons 
present in the sequencing capture set was calculated to determine if the CNV could 
be detected via WES. In total, 97% of the CNVs contained three or more exons, the 
minimum number required for WES-based CNV calling by CoNIFER. The majority 
of CNVs in this larger set of clinically relevant CNVs were larger than 200 kb in size 
(96%), whereas only half of CNVs from the rare consensus set (13/25) were in this 
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size range. WES achieved a detection rate of 75% for CNVs smaller than 200 kb, 
and 100% for CNVs larger than 200 kb. When we apply these detection rates to the 
clinically relevant CNVs, it is predicted that 96% (453 CNVs) of these CNVs would 
have been successfully identified by WES. Based on the limited number of CNVs 
included in this study, this theoretical detection rate is in line with the observed 
experimental detection rate of 92% (i.e., 11 of the 12 clinically relevant CNVs being 
successfully detected).
DISCUSSION
CNV is a common source of genetic variation that has been implicated in many 
genomic disorders [Cooper et al., 2011; Lupski, 2009; Stankiewicz and Lupski, 
2010]. This has resulted in the widespread application of genomic microarrays as 
a first-tier diagnostic tool for CNV detection [Mefford and Eichler, 2009; Miller et 
al., 2010; Stankiewicz and Beaudet, 2007; Vissers et al., 2010]. The introduction of 
massive parallel sequencing approaches has provided a valuable tool for mutation 
identification in rare and genetically heterogeneous disorders [Bamshad et al., 2011; 
de Ligt et al., 2012; Gilissen et al., 2012; Gonzaga-Jauregui et al., 2012; Hanchard 
et al., 2013; Ng et al., 2010; O’Roak et al., 2012; Rauch et al., 2012]. For example, 
in a genetically heterogeneous disorder such as ID, a causal or candidate (de novo)
mutation was identified in up to 38% of cases [de Ligt et al., 2012; Rauch et al., 
2012], and it has been reported that an additional 10%-20% of ID cases can be 
explained by clinically relevant de novo CNVs [Mefford et al., 2012]. Therefore, the 
addition of CNV detection from WES data could achieve a diagnostic yield up to 
58%, with a single test, for ID. This would represent the highest diagnostic yield of 
any current clinical genetic screening method for this disorder. A single genomic 
assay, which detects all forms of genomic variation, could decrease the time to 
obtain a molecular diagnosis, and reduce the diagnostic odyssey faced by patients 
and families.
Here, we evaluated the utility of WES to detect known clinically relevant CNVs in 
10 patients. We tested four different CNV detection algorithms for WES data and 
compared their results to CNVs detected by three different genomic microarray 
platforms. These results provide insights into the possibilities and limitations of 
CNV detection using different experimental platforms currently available, as well 
as the performance of CNV identification algorithms with both WES data and high-
resolution genomic microarrays.
Of the four algorithms tested in this study, CoNIFER was found to perform best with 
the highest TP rate and the lowest FN rate for the detection of rare coding CNVs. 
It is likely that CoNIFER performs especially well for rare CNVs due to the rigorous 
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correction for systematic fluctuation, as well as enrichment, sequencing, and 
mapping biases, by singular value decomposition and the use of a Z-score approach, 
which corrects for positional fluctuation across samples. The FN rate of CoNIFER 
was greater for common CNVs, which is likely due to the Z-score approach applied 
for copy number estimation. The Z-score corrects for the fluctuation of a data 
point in the reference set; as a result, CNVs occurring in a region where reference 
samples are variable will have a lower Z-score compared with the same CNVs in a 
copy number stable region. Additionally, we limited our analysis to read algorithms 
suitable for short (50 bp) single-end reads as sequenced by SOLiD chemistry because 
read-depth algorithms are applicable to most WES approaches [Bamshad et al., 
2011]. When longer reads or read pairs are available, more sophisticated methods 
can be used to increase the detection power for CNVs by combining different lines 
of evidence such as split read and clustering of discordant pairs [Teo et al., 2012] 
with a wider range of available programs [Duan et al., 2013]. 
Identifying CNVs in WES data is subject to a number of limitations due to the uneven 
spacing of exons, and thus data points, across the genome [Teo et al., 2012]. This 
affected the identification of the CNV segments, which in four cases were over 
segmented and reported as several smaller CNVs, requiring merging during post-
processing. Likewise, the unequal spacing of the genomic data points also influenced 
the identification of the CNV breakpoints.
In general, the maximum possible size of the CNVs was reported; and in the 
absence of data points, segments were continued until a normal copy number 
signal was detected. Alternatively, CNV breakpoints can be identified based on the 
last occurrence of an aberrant copy number signal, the minimum CNV size. The 
difference between the maximum and minimum predicted CNV size as called by 
WES varied between 2.8 and 542.8 kb across the 11 de novo CNVs. Reporting both 
the maximum and minimum possible CNVsize provides useful insights into the 
uncertainty of breakpoint predictions.
Most clinically relevant CNVs currently detected by routine screening are large 
(Supplementary Figure S2) and often contain multiple genes. Likewise, the CNVs 
identified in this study using WES were biased to larger CNVs containing multiple 
exons. However, our results using high-resolution microarrays indicate a large 
number of smaller single exon CNVs may exist within these samples (Supplementary 
Table S2). Likewise, data from personal genomes [Wheeler et al., 2008], high 
resolution CGH arrays [Conrad et al., 2010], and WES [Mills et al., 2011] indicate 
that the genomes of healthy individuals harbor 600-900 [Korbel et al., 2008; Levy 
et al., 2007] CNVs with a median size of 0.7 kb. Validation experiments of the 4.2M 
NimbleGen microarray (ExonArray) showed that this platform has the potential to 
reliably detect known single exon deletions, and screening for exon level CNVs in a 
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clinical setting has revealed multiple small, causal events [Boone et al., 2010;Whibley 
et al., 2010]. These small CNV events have been largely invisible to commercial 
genome-wide microarrays and remain challenging to detect through WES. While 
the detection specificity and sensitivity of the platforms used in this study is unclear 
for these small CNVs, it is apparent that these events occur frequently and could 
contribute to the patient’s phenotype. Thorough validation studies of these very 
small CNVs are required to establish their frequency and possible contribution to 
disease.
While the current detection power of WES, especially for single exon CNVs, does 
not match that of high-resolution microarray platforms, we show that WES data are 
suited for the detection of large, rare, genic events that represent the majority of 
currently reported clinically relevant CNVs. A likely reason why the single exon 15 kb 
deletion included in this study was difficult to detect is that each exon represents a 
single data point. Detecting the difference between signal and experimental noise 
based on one data point requires very little fluctuation or noise. Possible solutions 
for larger exons include subdivision of exons into smaller regions to create multiple 
data points, or in the case of deletions, to include homozygosity data from SNVs into 
the detection algorithm. Ongoing developments in CNV identification algorithms 
will likely result in further performance improvements [Amarasinghe et al., 2013; 
Fromer et al., 2012].
The reliable detection of rare, genic CNVs is a valuable adjuvant tool within the 
clinical setting when WES data are available. Possibilities to enhance the detection 
power for CNVs of WES approaches include larger capture kits, the addition of a 
genomic backbone to improve genome-wide resolution, and/or the addition of 
intronic capture sequences to improve the accuracy in determining which exons 
are affected by a CNV. Improvements in data analysis could be made by applying 
more sophisticated normalization methods to account for biases introduced during 
the capture and sequencing procedures. In addition, current WES CNV detection 
algorithms used in this study are limited in breakpoint accuracy by the read-
depth approach and could be further improved by incorporating information from 
genotypes, split-reads, and read-pair information to increase the detection power 
of WES for CNVs [Mills et al., 2011]. While these improvements are of great benefit 
to further increase WES-based CNV detection, the results presented in this study 
show that CNV detection resolution of exome sequencing is already comparable to 
that of medium-resolution genomic microarrays currently used as clinical assays.
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ABSTRACT 
Blood plasma of pregnant women contains circulating cell-free fetal DNA (ccffDNA), 
originating from the placenta. The use of this DNA for noninvasive detection of 
fetal aneuploidies using massively parallel sequencing (MPS)-by-synthesis has 
been proven previously. Sequence performance may, however, depend on the 
MPS platform and therefore we have explored the possibility for multiplex MPS-by-
ligation, using the Applied Biosystems SOLiD 4 system. DNA isolated from plasma 
samples from 52 pregnant women, carrying normal or aneuploid fetuses, was 
sequenced in multiplex runs of 4, 8 or 16 samples simultaneously. The sequence 
reads were mapped to the human reference genome and quantified according to 
their genomic location. In case of a fetal aneuploidy, the number of reads of the 
aberrant chromosome is expected to be higher or lower than in normal reference 
samples. To statistically determine this, Z-scores per chromosome were calculated 
as described previously, with thresholds for aneuploidies set at > +3.0 and < -3.0 for 
chromosomal over- or under representation, respectively. All samples from fetal 
aneuploidies yielded Z-scores outside the thresholds for the aberrant chromosomes, 
with no false negative or positive results. Full-blown fetal aneuploidies can thus be 
reliably detected in maternal plasma using a multiplex MPS-byligation approach. 
Furthermore, the results obtained with a sample from a pregnancy with 45,X in 
the cytotrophoblastic cell layer and 46,XX in the mesenchymal core cells show that 
ccffDNA originates from the cytotrophoblastic cell layer. Discrepancies between 
the genetic constitution of this cell layer and the fetus itself are well known, and 
therefore, care should be taken when translating results to the fetus itself.
INTRODUCTION
For the prenatal detection of chromosomal aberrations, fetal material is needed 
which, until recently, could only be obtained via invasive procedures such as 
chorionic villus sampling (CVS) or amniocentesis (AC). These procedures entail a 
minor but definite risk of miscarriage, and therefore CVS and AC are only offered to 
pregnant women at relative risk of carrying a fetus with a chromosomal aberration.
Since 1997, however, it is known that plasma of pregnant women contains circulating 
cell-free fetal DNA (ccffDNA) [1]. As this ccffDNA can be obtained via maternal 
blood sampling, it represents an attractive source of fetal material for non-invasive 
prenatal diagnosis (NIPD). Within this context, several characteristics of this ccffDNA 
have been studied extensively. Compared with fetal cells in the maternal circulation, 
the concentration of ccffDNA in maternal plasma is relatively high and the fetal/
maternal DNA concentration ratio favorable (estimates: ~ 3-19% of the DNA in the 
plasma is of fetal origin [2-4]). This turns ccffDNA into a more attractive source for 
NIPD than intact fetal cells in the maternal circulation. Additionally, ccffDNA has a 
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very short half-life time (mean 16.3 minutes) and will, therefore, not be detected 
in the maternal circulation after delivery [2]. The ccffDNA has been shown to be 
derived from the placenta and is, therefore, extraembryonic in origin [5-8]. The 
placental DNA is released into the maternal circulation by apoptosis, explaining the 
highly specific fragmented nature of ccffDNA [3,9]. Taken together, ccffDNA may 
offer a range of possibilities for application in NIPD.
In 2008, two research groups independently showed that ccffDNA can be used 
for NIPD of fetal trisomies using massively parallel sequencing (MPS)-by-synthesis 
[3,10]. In short, DNA fragments, isolated from maternal plasma samples containing 
DNA both fetal and maternal in origin, were used for MPS taking advantage of 
the fact that through MPS several hundreds of millions DNA fragments can be 
sequenced and quantified at once. These fragments were subsequently mapped 
to the human reference genome and the (relative) numbers of fragments per 
chromosome were counted. Hence, if the fetus carries a trisomy, more fragments of 
the trisomic chromosome are expected to be mapped to the specific chromosome 
when compared with the other normal (diploid) chromosomes. The initial proof-
of-concept studies showed that this method allowed a correct prediction of fetal 
trisomies 21 (n=23), 13 (n=1) and 18 (n=2), without false negative or positive results 
[3,10]. Since then, several large-scale studies have shown that MPS-by-synthesis 
can be used (also in a clinical setting) for non-invasively diagnosing fetal trisomy 
21 [11-14]. As such, this test is to date commercially offered to pregnant women 
in the USA. The efficacy to detect other fetal trisomies, such as trisomy 13 and 
18, has also been studied. The detection of these trisomies, however, appeared 
to be less accurate when the same statistical algorithm as for the detection of 
trisomy 21 was applied [15], which was attributed to a lower GC content of these 
chromosomes. However, when using adapted algorithms also trisomies 13 and 18 
could be identified correctly with MPS-by-synthesis methods [13,15].
So far, almost all studies dealt with MPS-by-synthesis methods using the Illumina 
GA(II) or HiSeq 2000 platforms. It is, however, known that sequence performance 
and ability to multiplex samples depend on the MPS platform used. In our 
laboratory, MPS-by-ligation is routinely performed using a SOLiD 4 platform (Applied 
Biosystems/Life Technologies, Foster City, CA, USA) in both postnatal diagnostic and 
research settings. As such, we aimed in the present study to technically evaluate 
the possibility to perform NIPD with ccffDNA for the detection of fetal aneuploidies 
using MPS by-ligation, simultaneously testing the possibility of multiplexing 
samples. Moreover, we established the placental cell layer origin from which cffDNA 
is derived.
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Table 1. Overview of the samples from pregnancies with fetal aneuploidies, including 
run number, gestational ages and Z-scores for the aberrant chromosomes with different 
algorithms.
Sample 
number Aberration
Run 
number
Gestational 
age
Collected 
before
or after an 
invasive
procedure
Aneuploid 
autosomal 
Z-scores
ALG1 ALG2
A Trisomy 13 35 13.2 5 days after CVS 9.12 -
B Trisomy 13 109 19.2 Before 6.25 5.10
C Trisomy 18 35 15.1 10 days after CVS 11.60 -
D Trisomy 18 45 13.0 Before 13.62 -
E Trisomy 18 45 20.3 8 days after AC 9.52 -
F Trisomy 18 63 12.6 7 days after CVS 4.70 5.14
G Trisomy 21 18 12.4 6 days after CVS 5.28 -
H Trisomy 21 35 19.6 7 weeks after CVS 7.29 -
I Trisomy 21 45 21.1 6 days after AC 3.12 -
J Trisomy 21 45 15.4 Before 7.51 -
K Trisomy 21 45 12.4 4 days after CVS 5.80 -
L Trisomy 21 63 20.3 8 weeks after CVS 5.80 11.81 
M Trisomy 21 63 13.2 2 days after CVS 8.29 16.56 
N Trisomy 21 63 15.5 Before 3.38 7.17 
O* Trisomy 21 109 13.5 Before 4.73 4.62 
P Trisomy 21 109 10.5 Before 10.22 10.13 
X-chromosome Z-scores
Q 47,XXX 35 19.1 3 weeks after AC 5.23
R
CVS: 45,X[8] (STC) 
and 46,XX[25] (LTC) 
AC: 46,X[1]/ 
46,XX[28] 
Newborn blood: 
46,XX[30] 
63 16.1
20 days after CVS, 
before AC
-7.72
S 45,X 109 11.1 before -5.62
* Processing of this sample was carried out 7½ h after collection of the blood.
AC: Amniocentesis; CVS: Chorionic villus sampling; LTC: Long-term culture; STC: Short-term 
culture; -: Not determined.
93
N
on-invasive prenatal diagnosis using M
PS
Chapter 5
STUDY DESIGN / MATERIALS AND METHODS
SUBJECT ENROLLMENT
Pregnant women were recruited at the Department of Obstetrics and Gynecology, 
Radboud University Nijmegen Medical Centre, Nijmegen, and the Department of 
Obstetrics and Gynecology, Rijnstate Ziekenhuis, Arnhem, The Netherlands. The 
study was approved by the ethical committee. All pregnant women received written 
and oral information regarding the study and from all pregnant women signed 
informed consent was obtained.
PATIENTS AND SAMPLES
From 52 pregnant women (singleton pregnancies for which an invasive procedure 
was indicated) at various gestational ages blood samples (20-40 ml in EDTA 
(ethylenediaminetetraacetic acid) anti-coagulated tubes) were collected. Genetic 
fetal analyses were diagnostically carried out on AC or CVS cells by either QF-PCR 
only (Aneufast kit, version 2, Genomed Ltd., Kent, UK), routine karyotyping (both 
according to standard protocols) or 250k SNP array analysis (according to the 
protocol described by Faas et al. [16]). Fetal karyotypes from samples from abnormal 
pregnancies, always confirmed by routine diagnostic karyotyping, are listed in Table 
1. These samples were drawn either before or after an invasive procedure. All blood 
samples from pregnancies with normal fetuses were drawn before an invasive 
procedure. The mean gestational age of the normal pregnancies was 12.2 weeks 
(range 8.5-16.1 weeks): 28 samples were from normal first trimester pregnancies, 5 
from second trimester pregnancies.
All blood samples were kept on room temperature before processing and all, 
except for sample O, were processed within 6 h after collection by centrifugation 
at 1600g for 10 minutes, separating plasma from the buffy coat. Sample O was 
processed after ~7½ h. The plasma was then transferred to 1.5 ml Eppendorf tubes 
and recentrifuged at 16,000g. The supernatants were collected and stored at -80 °C 
until further processing.
DNA ISOLATION
Plasma DNA was isolated from 3.2 to 7 ml of the frozen plasma samples using a 
QIAamp DSP DNA Blood Mini Kit or a QIAamp Circulating Nucleic Acid Kit (QIAgen, 
Westburg BV, The Netherlands) with minor modifications (exact protocol available 
on request). Briefly, each plasma sample was divided into two aliquots and for each 
of these aliquots one isolation column was used. DNA was eluted in 100 μl of low TE 
buffer (Applied Biosystems, Carlsbad, CA, USA) in Eppendorf DNA LoBind tubes. Of 
note, the elute of the first column was used as elution buffer for the corresponding 
second column. The total amount of isolated DNA varied from 8.9 to more than 100 
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ng per sample. DNA quality was checked using a Bioanalyzer High Sensitivity assay 
(Agilent Technologies, Waldbronn, Germany). After isolation, DNA samples were 
stored at 4C until further use. 
MASSIVELY PARALLEL SEQUENCING-BY-LIGATION
Library preparation; Sequencing libraries were prepared individually following the 
Applied Biosystems protocol for Barcoded Fragment Library preparation (version 
March 2010), without performing the sonication of DNA for generating short 
fragments, as the ccffDNA is already fragmented in nature. For testing efficacy of 
multiplexing, all samples but those in run 18, were labeled using unique identifier 
tags or barcodes (Agilent) that were compliant with SOLiD sequencing technology.
Bead enrichment; The four libraries sequenced in run 18 were not barcoded and, as 
such, were individually subjected to a manual emulsion PCR and bead enrichment 
(SOLiD 4 System Templated Bead Preparation QRC, Rev B 03/2010. Remark: 0.5 
pM used as input for emPCR). For multiplexed sequencing runs (runs 35 (8-plex), 
45 (16-plex), 63 (16-plex) and 109 (16-plex)), finished libraries were equimolarly 
pooled for multiplexing up to 16 samples simultaneously with a final combined 
library concentration of 700 pM. Subsequently, the obtained pool was used for 
emulsion PCR (E80 scale) and bead preparation using the EZ bead system, following 
manufacturer’s instructions (version May 2010; Life Technologies).
SEQUENCING
Massively parallel whole genome sequencing-by-ligation was performed on a SOLiD 
4 System (Life Technologies, Foster City, CA, USA), according to the manufacturer’s 
protocol. After 3’ end modification, enriched beads were quantified using 
a Nanodrop. For each of the four samples in run 18, one quad of a sequencing 
slide was used, whereas for each multiplexed pool (runs 35, 45, 63 and 109), a 
full sequencing slide was used (Life Technologies, Carlsbad, CA, USA). For multiplex 
sequencing runs, we anticipated that all samples in the pool would be equally 
represented in the total number of beads present on the sequencing slide.
MAPPING
The 50-bp color space reads were mapped to the hg19 reference genome with 
the SOLiD bioscope software v1.3, which utilizes an iterative mapping approach. 
Fragments of which at least 30 bp were mapped were included for further analyses. 
Additionally, only reads with a minimum mapping quality (MAPQ) of 60 (PHRED 
scaled) were used for read counting (allowing a maximum of 1 mismatch for 
fragments with read lengths between 30 and 47 bp and a maximum of 2 mismatches 
for fragments with read lengths between 48 and 50 bp). These quality criteria result 
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in mapped reads with a 0.001% chance of being misaligned, thereby drastically 
reducing multiple mapping artifacts.
DATA ANALYSIS
AUTOSOMAL CHROMOSOMES
For all samples, Z-scores were calculated as previously described [10]. First, the 
percentage of reads of a chromosome of interest of the total number of reads of a 
sample was determined, using the following equation:
 a = chromosome of interest
 # reads = reads passing the MAPQ filter step (within a single sample)
Subsequently, this percentage was compared with the mean percentage of the 
same chromosome of a set of reference samples, and Z-scores were calculated 
using the following equation:
 a = chromosome of interest
 reference %a = values as observed in control samples
For algorithm 1 (ALG1), all samples in a run, regardless of the fetal karyotype, were 
used as reference samples. As this also includes samples from pregnancies with 
abnormal karyotypes, for the calculation of the mean of a specific chromosome, 
the aberrant sample was excluded. For algorithm 2 (ALG2), mean percentages 
were calculated by combining results from normal males from different runs as 
references. Thresholds for aneuploidy were set at Z > +3 and Z < -3 for over- or 
under representation, respectively.
DETERMINATION OF FETAL GENDER
Similar to others [10,11,17], we also detected the presence of Y-chromosome-specific 
sequences in samples from female pregnancies. Therefore, for determination of 
the fetal gender, first the percentages of reads of both the X- and Y-chromosomes 
# reads on a
# reads on all chromosomes
%a = * 100 
%a - mean ( reference %a )
SD ( reference %a )
Z-score = 
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in reference males and females were determined as described above (see Section 
2.5.1). Obtained values were used to determine the indicative value for the presence 
of a Y-chromosome and, subsequently, fetal gender of the samples was predicted. 
For all samples, determined as not carrying Y-chromosome specific sequences, 
the X-chromosome Z-score was calculated, using an algorithm comparable with 
ALG1, with normal females as references (in case insufficient samples from normal 
female fetuses were available in one run, samples from (autosomal) chromosomally 
abnormal fetuses were also used as a reference). This algorithm was termed ALGX.
RESULTS
TECHNICAL FACTS
In this study, samples sequenced in 4-, 8- and 16-plex runs were included. Runs 18, 
35 and 45 were considered to be runs in the learning phase. Runs 63 and 109 were 
technically considered optimal and in these runs the mean number of good quality 
reads per sample that met our criteria was 18.3 x 106 (standard deviation (SD) 3.8 
x 106: maximum 23.5 x 106, minimum 9.5 x 106; on average 63% of the number of 
raw reads).
DETERMINATION OF AUTOSOMAL (AN)EUPLOIDIES
ALG1 was applied to all runs and for all samples and all autosomal chromosomes 
revealed Z-scores as expected: all trisomies 13 (n=2), 18 (n=4) and 21 (n=10) 
showed Z-scores > 3.0 for the trisomic chromosomes with Z-scores within the 
normal range for the other chromosomes (Table 1). ALG1, however, requires pre-
test knowledge of the fetal karyotypes, as for calculation of the mean percentage of 
reads of a chromosome of interest all samples in a run are included and in case of an 
aberration, an adjustment for the aberrant chromosome is carried out. Therefore, 
for runs 63 and 109 Z-scores were also calculated with ALG2, for which no pre-test 
knowledge is necessary. This yielded Z-scores for all samples as expected (Table 1 
& Figure 1), with no false positive or negative results. The standard deviation of 
the means of the various chromosomes in the reference male samples, indicative 
for the variation between normal samples, ranged from 0.006 for chromosome 
14 to 0.210 for chromosome 4. For chromosomes 13, 18 and 21, this was 0.084, 
0.025 and 0.008, respectively. Figure 2 shows a schematic overview of the standard 
deviations of the means using ALG2.
DETERMINATION OF SEX CHROMOSOMES
For runs 18, 35 and 45, the percentages of Y-chromosome specific sequences varied 
per run. Nevertheless, based on the percentages in normal males and females, 
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Figure 1. Boxplot with Z-scores of the autosomal chromosomes, when applying ALG2. 
The samples with Z-scores > 3 are the samples from runs 63 and 109 with abnormal fetal 
karyotypes, as listed in Table 1.
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Figure 2. Standard deviations (SD) of the means of the autosomal chromosomes, when 
applying ALG2.
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for all three runs a relatively high or low percentage of Y-chromosome-specific 
sequences could be correctly correlated to the presence or absence, respectively, 
of a Y-chromosome. Both samples Q (fetal 47,XXX; run 35) and R (fetal 45,X/46,XX; 
run 45 (also included in run 63)) showed less Y-specific sequences than samples 
from normal male pregnancies, indicating the absence of a Y-chromosome. For runs 
63 and 109, the mean percentages of Y-chromosome specific reads in samples from 
normal fetal males and females were comparable in both runs and combining both 
runs resulted in 0.018% (SD 0.001: highest 0.019%, lowest 0.016%) for samples 
from normal fetal females and 0.033% (SD 0.009: highest 0.052%, lowest 0.025%) 
in samples from normal fetal males. The presence or absence of a Y-chromosome 
could be predicted correctly in all samples and both sample R (fetal 45,X/46,XX; 
run 63) and S (fetal 45,X; run 109) revealed percentages of Y-chromosome 
specific sequences comparable with normal female samples (0.023 and 0.019%, 
respectively). Subsequently, for samples predicted as not having Y-chromosome- 
specific sequences, Z-scores for the X-chromosome were calculated, according to 
ALGX. The fetal sex was predicted correctly in all cases, including samples Q (fetal 
47,XXX: X-chromosome Z-score 5.27), R (fetal 45, X/ 46,XX: X-chromosome Z-score 
-7.73) and S (fetal 45,X: X-chromosome Z-score -5.62).
CONCLUSIONS
From this technical evaluation study we conclude that for the non-invasive 
detection of fetal autosomal aneuploidies from ccffDNA in maternal plasma MPS-
by-ligation with the SOLiD 4 platform can be applied, and that sequencing of up 
to at least 16 samples simultaneously is possible on this platform. As the first runs 
(runs 18, 35 and 45) contained relatively few samples from normal pregnancies 
that could serve as reference samples, ALG1 was applied. With this algorithm the 
presence or absence of autosomal aneuploidies could be predicted correctly. ALG1, 
however, requires a priori knowledge of the fetal karyotypes and thus cannot be 
used in a clinical diagnostic setting. Therefore, after this learning phase, another 
algorithm for which no pre-test knowledge is necessary (ALG2), was applied. 
With this algorithm, only samples from normal male pregnancies were used as 
references to calculate the mean percentage of reads of a specific chromosome and, 
subsequently, Z-scores from all samples from two different runs were calculated: 
all fetal autosomal aneuploidies, including trisomies 13, 18 and 21, could be 
predicted correctly with no false positive or negative results. Also, the fetal sex and 
sex chromosomal aneuploidies could be predicted correctly by first determining 
the presence or absence of a Y-chromosome and, subsequently, determining the 
number of X-chromosomes in the Y-chromosome-negative samples.
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Additionally, evidence is provided that ccffDNA in the maternal plasma is derived 
from the cytotrophoblastic cell layer of the placenta, as results obtained with 
sample R are suggestive for the presence of one X-chromosome in the absence of a 
Y-chromosome. This is in line with the fetal karyotyping results obtained with cells 
from the cytotrophoblastic cell layer of the placenta, and not of the mesenchymal 
core cells of the placenta, neither of the AC cells nor the cells from the newborn 
blood.
EXPERT OPINION
Cell-free fetal DNA is present in the plasma of pregnant women in relatively large 
amounts and in a relatively favorable percentage of the total amount of DNA in 
the plasma. As this DNA can be obtained via non-invasive procedures, it represents 
an attractive source for NIPD. So far, several studies have shown the possibility of 
using MPS-by-synthesis with cffDNA for the detection of fetal trisomy 21, including 
two large-scale studies in a clinical setting [3,10-14]. Since not all laboratories are 
equipped with the same platform and different platforms may exhibit different 
performances, we set out to test the efficacy of the Applied Biosystems SOLiD 4 
platform. To our best knowledge, so far only one study has described the successful 
use of MPS-by-ligation for NIPD of trisomy 21 using the SOLiD 3 system of Applied 
Biosystems [17]. In the present study, we confirm their results with MPS-by-
ligation, in our setting using the SOLiD 4 platform, and show on 52 samples that this 
platform indeed can be applied for the robust and reproducible detection of fetal 
aneuploidies with ccffDNA from plasma of pregnant women.
As can be seen from Table 1, not all aneuploid samples were collected before 
an invasive procedure. One might argue this influences the results, as additional 
fetal DNA might be released into the maternal circulation as a consequence of the 
invasive procedure. To the best of our knowledge, however, there exists no evidence 
for such a procedure related increase in ccffDNA. Moreover, the blood was always 
collected several days up to several weeks after CVS or AC. Even if there had been 
a procedure-related increase of ccffDNA, this would not be detectable anymore in 
our samples, because of the very short half-life time of the cffDNA [2].
The present study was not restricted to the detection of fetal trisomy 21, as two 
fetal trisomy 13 and four fetal trisomy 18 cases were included and diagnosed 
correctly too, using the same algorithm as for the diagnosis of fetal trisomy 21. 
Previously, others argued that this algorithm might be less accurate for diagnosing 
fetal trisomy 13 and 18 [15] as, due to the GC content of these chromosomes, there 
is a broader sample to sample variation in number of reads per chromosome, as 
compared with chromosome 21. Therefore, they suggested the use of an algorithm 
with GC-correction for calculating Z-scores [15]. Also Sehnert et al. used a different 
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approach to correctly identify fetal trisomy 18 [13]. In the present study, we indeed 
observed a broader sample-to-sample variation for chromosomes 13 and 18 than 
for chromosome 21, as reflected by the SD of the means, which were 0.084, 0.025 
and 0.008, respectively (Figure 2). We were, however, able to correctly predict fetal 
aneuploidies in all cases using ALG1 or ALG2, suggesting that with MPS-by-ligation 
using the SOLiD 4 platform, no GC-correction is necessary for reliable diagnosis 
of fetal trisomy 13, 18 or 21. We do, however, realize that our conclusion might 
be biased by our relatively small sample size for trisomies 13 and 18 (n=2 and 4, 
respectively).
In our setting, we multiplexed up to 16 samples, which resulted in ~ 18 x 106 good 
quality reads per sample, with ~ 9 x 106 reads being the lowest number of reads 
achieved per sample. Previously, others showed with MPS by-synthesis that a 
minimum of between 0.3 and 2.3 x 106 good quality reads per sample are necessary 
for reliable results [11]. As we expect this to be comparable for MPS-byligation it 
must, theoretically, be possible to obtain a threefold higher multiplexing sequencing 
rate than presented here, thereby significantly reducing costs. Further studies to 
test this are in motion. Even though the results of the present study are in full 
concordance with the results obtained with invasive prenatal diagnosis, we did not 
include a test to check for the presence of fetal DNA, in case a normal female fetus 
was predicted. Before the test is implemented in routine daily prenatal practice, 
such a check, as also described by others [12], should be incorporated.
In summary, we conclude that the issue is no longer whether NIPD for fetal 
aneuploidies is possible, as we and others have now shown that both MPS-by-
synthesis and MPS-by-ligation can be reliably used, but how it can be implemented 
in the daily practice of prenatal diagnosis. Nowadays, the first trimester screening 
is offered routinely to pregnant women. With this non-invasive test, however, a risk 
on fetal trisomy 13, 18 and 21 is calculated, whereas NIPD by MPS results in definite 
diagnosis. Even though for the time being first trimester screening is a much cheaper 
and quicker method than NIPD with MPS, the latter is expected to replace the first 
trimester screening in the near future, as prices will drop and turnaround times of 
MPS will improve. As a result of the much higher predictive value of NIPD with MPS, 
the number of invasive procedures will probably be reduced significantly as invasive 
procedures will mostly be restricted to those pregnant women with a positive NIPD
result. Nuchal translucency (NT) measurement is currently used in first trimester 
screening as part of risk assessment for trisomy 13, 18 and 21, but this measurement 
alone may also identify pregnancies at a high risk of non-chromosomal disorders, 
such as congenital heart defects and monogenetic disorders, such as Noonan 
syndrome [18]. Therefore, one could opt for keeping NT measurement in place as a 
separate screening test, complementary to NIPD.
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Even though ccffDNA in the maternal plasma is a very attractive source of fetal 
DNA for NIPD, one should be aware of the fact that the fetal DNA that is studied 
with NIPD is extraembryonic in origin and reflects the genetic constitution of the 
cytotrophoblastic cell layer of the placenta, rather than the mesenchymal core cell 
layer. Discrepancies between the cytotrophoblastic cell layer of the placenta and 
the fetus itself are well-known. Therefore, one might opt for a strategy in which all 
NIPD-positive cases are offered AC, or at least those cases of aneuploidy of which 
discrepancies between the cytotrophoblastic cell layer and the fetus itself are 
known to occur (e.g., trisomy 18).
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THE EVOLUTION OF GENETICS AND (BIO)INFORMATICS
In 1860 the study of genetics began with Gregor J Mendel investigating the 
inheritance of traits in pea plants [1]. As time progressed, geneticists were able to 
study more traits with, for example Drosophila, studied in the famous fly room of 
Thomas H Morgan [2]. Morgan envisioned traits as being physically linked and this 
resulted in the creation of the first chromosome map in 1911 by Alfred Sturtevant 
[3]. The concept of observing and mathematically describing traits is of particular 
relevance for the application of computational methods to the genetics field [2]. 
Studying inheritance in plants and animals was essentially of a quantitative nature, 
therefore many early geneticists used and developed statistical and quantitative 
methods for their research [2].
Figure 1, timeline depicting important breakthroughs for the fields of (bio)informatics (top) 
and genetics (bottom).
Amongst the many mathematicians who brought statistics to the genetics field 
[2], there is one of special interest for the emergence of bioinformatics; John J 
Haldane, famous for his early estimates of human mutation rates [4] (Figure 1). 
Haldane’s observations demonstrated the power of applying mathematical models 
to biological observations. One other important mathematician is Alan Turing, 
one of the founding fathers of information theory who formalized the concepts 
of algorithms and computation [5]. Turing provided the means to apply these 
statistics to more complex problems in a structured and systematic manner, one 
of the foundations of bioinformatics. The early successes of statistics led to the 
(Bio)informatics
 Genetics
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Box 1, Schrödinger’s cat refers to a thought experiment which illustrates how probabilities 
resolve into fixed states [1], it describes a scenario in which an imaginary cat is equally 
likely to be dead or alive (in terms of probabilities), while in reality one immediately 
realizes that the cat must be either one or the other. The original experiment served 
to illustrate a paradox in quantum mechanics, it can now be applied to genetic testing 
results. For example; when considering the risk of disease, an individual can have equal 
risks of being affected or not while in reality that person will be either affected or healthy. 
We can use probabilities to predict something about a group of individuals well, while 
it can be difficult to apply to a single individual. Until all factors contributing to risks and 
modifiers are understood interpreting chance will be an essential part of genetic testing 
and counseling.
[1] Schrödinger E. Die gegenwärtige Situation in der Quantenmechanik 
Naturwissenschaften 23, 807-849 (1935). (The present situation in quantum mechanics). 
Translation available at; www.tuhh.de/rzt/rzt/it/QM/cat.html
merging of genetics and complex mathematics, ultimately resulting in the field 
of bioinformatics. Bioinformatics uses (bio) statistics to test hypotheses on large 
quantities of data, through a large number of complex calculations. The field 
distinguishes from biostatistics by the incorporation of informatics concepts such 
as neural networks, graph theory, process optimization, file handling, database 
operations, prediction models and detection algorithms [2,6].
Similar to the concept of traits having a physical distance, the concept of DNA 
as a code formed an important link between genetics and information theory. In 
1946 Erwin Schrödinger (owner of a well known imaginary cat [box 1]) envisioned 
chromosomes to contain a “code-script” [7]. According to Schrödinger’s reasoning 
an entity which could read and interpret the chromosomal code would be able to 
“tell from their structure whether the egg would develop … into a black cock or a 
speckled hen …” [2,7]. This notion of DNA code is highly similar to the concepts 
introduced by Turing in his work on algorithms; a structured set of commands to 
perform complex calculations encoded in a computer [5].
Subsequent research of the ‘chromosome code’ uncovered a high degree of 
similarity between computer and genetic code; DNA encodes information in four 
nucleotides; A, T, C and G and computers encode information binary (1 or 0) [2]. 
While DNA codes are chemically encoded and computer codes mostly electronically, 
both methods use a relative simple set of elements as building blocks to construct 
an immense quantity of complex commands and structures.
The first application of a programmed computer to solve a biological problem 
was published in 1950 [8] by Ronald A Fisher (therefore arguably the first 
bioinformatician), in which he used differential equations to compute gene 
frequencies in populations. Many of Fisher’s statistical tests, like the Fisher exact 
test and his analysis of variance (ANOVA) models are still used in genetic research 
to test hypotheses [2,6,9].
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Both bioinformatic and genetic research accelerated quickly through the work of 
James Watson and Francis Crick, who described the structure of DNA in 1953 [10]. 
The structure of DNA was described based on experimental data from Rosalind 
Franklin and Raymond Gosling [11], supported by the structure observed by Maurice 
Wilkings and colleagues [11]. In these early days, bioinformatics was perceived by 
many as a tool to process large quantities of data [12]. Biomedical researchers 
involved bioinformaticians after a hypothesis was formed and data were gathered 
to calculate quantitative values, for example, on sequence similarity [2,6]. The role 
of bioinformatics soon evolved into a more exploratory one by studying how DNA 
encoded proteins and to identify where these coding elements (genes) resided in 
the genome [6]. Through combined genetics and informatics efforts, the definition 
of a gene changed from an abstract unit of inheritance to a set of structured DNA 
sequences [13].
Similar to computer code, DNA sequences were found to contain operators telling 
the cells translation machinery where to start and stop translation [13]. However, 
it remained unclear how these DNA sequences encoded amino acids resulting in 
protein sequences. The presence of codons, encoded by a triplet sequence, was not 
immediately evident from the initial DNA sequences and was not solved in spite of 
many years worth of computational modeling [14]. Biologists in the lab of Marshall 
W Nirenberg eventually identified the first nucleotide triplet code for amino acid 
encoding in 1965 [15]. The identification of all codons by 1966 is referred to as “the 
cracking of the genetic code” [15], enabling researchers to start reading the protein 
coding parts of DNA [15]. The fields of genetics and bioinformatics were now 
collaborating more closely and by 1970 the first algorithms to perform sequence 
alignments were published [16,17]. The great interest in DNA sequences led to the 
introduction of the revolutionary sequencing technique developed by Frederick 
Sanger and colleagues in 1977 [18].
Computational methods were also spreading to other biology disciplines such 
as evolutionary biology using for example phylogenetic trees, proteomics using 
protein structure refinements and cellular biology using pathway analysis [6]. The 
high degree of integration of bioinformatics and genetics resulted in a blurring 
of the underlying disciplines [19], leading to changes in the perception of the 
bioinformatics field.
In 2003, Ouzounis and Valencia reviewed the rise and future of bioinformatics and 
stated “this discipline will continue to evolve rapidly into the 21st century, perhaps 
to a point beyond recognition” [6]. Indeed the field of bioinformatics has changed 
rapidly [19], geneticists now see computational analyses as “dry-lab” experiments, 
complementing and equal partner to “wet-lab” experiments [20,21]. I envision this 
trend to continue, and as a consequence every scientist in genetics will need to 
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understand the fundamental principles of information theory, algorithms, databases 
and statistical models.
While Sanger sequencing was well suited to study single genes it was not until new 
genetic technologies became available that researchers were able to routinely take 
a more holistic approach; Rather than studying one or a few genes they could now 
study all genes in a certain pathway or in an entire genome [2,22]. These large-scale 
approaches in genetics are referred to as genomics, the cousin of many other holistic 
approaches used in biology, collectively called ‘omics’ approaches [2]. The use of 
genomics approaches such as microarrays, aCGH and MPS, revolutionized genetic 
studies and caused an exponential increase in data and need for bioinformatics [19]. 
In first instance, these techniques required bioinformatics to handle the raw data 
coming from the genomics instruments. In such large-scale experiments error-
correction and noise-reduction models are essential to discern between signal and 
noise. For example models including a correction for GC content provided more 
accurate signals for microarray experiments while Hidden Markov Models enabled 
automated CNV identification in aCGH data [23,24]. In MPS experiments, read 
correction models and probability based variant identification methods were crucial 
for the reliable detection of genomic variants [25,26]. With this important role in 
the early stages of the experiment, bioinformatics has become an integral part of 
genetics research. A consequence of this is that improvements in data analysis have 
a substantial impact on the correct identification and subsequent interpretation of 
genomics data [25].
While it is safe to predict that the role of bioinformatics in genetics will continue to 
evolve, it is hard to predict exactly how or when. Predictions tied to technological 
advances are notorious for their limited validity. Such an example is the statement 
issued by Thomas Watson, president of IBM about computer usage in 1943: “I think 
there is a world market for maybe five computers”. This estimate was perfectly 
logical at the time when computers were as large as a room, now however it seems 
foolish in the view of a market size of over one billion computers worldwide. For 
this statement the large discrepancy between prediction and reality is attributed 
to the rapid decrease in computer size coupled to an exponential increase in 
computational power [27].
It is interesting to consider how miniaturization in both sequencing and 
computational approaches will affect genetics and bioinformatics. Genetics can 
benefit from informatics, as seen from the development of the IonTorrent™ (Life 
Technologies) technology [28]. This technology directly translates nucleotides, 
chemically encoded information, into digital information on a semiconductor chip 
through the measurement of Hydrogen release upon nucleotide incorporation [28]. 
Interestingly similar developments are also moving in the opposite direction, for 
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example the use of the DNA sequences to store data efficiently. DNA-based storage 
uses the four nucleotide encoding which is twice as efficient in terms of data density 
compared to the traditional binary encoding [29].
BIOINFORMATICS AND THE DETECTION OF GENOMIC VARIATION
Bioinformatics has played a crucial role in the implementation of both aCGH and 
MPS approaches in human genetic disease research and subsequent applications 
in diagnostics [25,30-33]. Bioinformatics was crucial for the optimization of CNV 
detection by aCGH in the beginning of this millennium [34], similar to its role now 
for CNV detection in MPS data [chapter 4,35]. Bioinformatics has also played a 
major role in the implementation of MPS technology in general, most notably in the 
following steps; i) sequence read processing ii) sequence read alignment iii) (small) 
variant identification and iv) variant annotation.
The first step in which bioinformatics played an important role was the sequence read 
processing, which is highly platform dependent due to the strong influences from 
the technical set-up including sequencing chemistry [36]. However, as sequencing 
technologies are becoming more sensitive and robust, with less sequencing errors 
and integrated error correction steps, post-experiment read-processing steps 
will become absolute [37]. Secondary steps such as read mapping and variant 
identification steps rely heavily on the reference genome, since the currently used 
fragmented short reads (50-175 bps) are not suited for the de novo (reference free) 
reconstruction of a genome. 
The reason why fragmented reads are not suited for de novo assembly is that 
assembly requires overlapping unique reads to construct scaffolds and unique 
scaffold spanning reads to merge these, which in general requires longer reads or 
specialized libraries [38]. It was recently shown that de novo assembly from short-
read paired-end genome sequencing misses approximately 16% of the genome, 
including over 2,300 coding exons [38]. The regions in which both reference based 
mapping and assembly based methods perform worst are the duplicated sequences 
[38]. Almost all duplicated sequences (99%) are missing or misaligned due to the 
inability of short-reads to be unique within these regions due to high degrees of 
sequence similarity [38].
Efforts continue to be made to delineate duplicated sequences within the human 
genome and thereby enable researchers to study the individual genomic locations 
using so called singly unique nucleotides (SUNs) in each of the locations [39,40]. The 
principle behind SUNs relies on the occurrence of random mutation, as can been 
exemplified using SRGAP2, an important gene in human brain development [41]. At 
least two duplications of this gene occurred specifically during human development 
approximately 3.4 and 2.4 million years ago [42]. Even though the copied segments 
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of the ancestral SRGAP2 gene are highly (>99.9%) identical, 16 nucleotides were 
found to have been affected by random mutation, making those regions unique to 
one of the copies [42]. 
Through intensive sequencing and genotyping efforts, scientists identified and 
localized three individual copies of SRGAP2 in the human genome; the ancestral 
SRGAP2 and two derivative copies, SRGAP2B and SRGAP2C [42,43]. Functional 
studies showed that the incomplete copies (B and C) are expressed and translated, 
and result in truncated forms of the original protein [43]. The protein derived from 
SRGAP2C was found to inhibit the ancestral SRGAP2 protein. This inhibition delays 
spine maturation and results in increased density and length of neuronal spines, 
neuronal features which are considered to be human specific [43]. These and other 
studies have shown the importance of the correct identification of duplicated 
sequences and their pivotal role in human evolution and genetic disorders [42-45]. 
It is important to note that the current human genome reference sequence does 
not account for most of these duplicated sequences, making these inaccessible to 
current genetic testing [38].
Technological advances will result in sequencing platforms which produce ever 
longer and more reliable sequencing reads [37,46]. Longer reads will reduce the 
time and complexity of the mapping process exponentially as they have a higher 
likelihood to be unique and therefore easier to map. Additionally the availability of 
longer reads means that fewer reads will be needed to achieve the desired coverage. 
When reads can be mapped with greater certainty, the variant identification 
step will also become more accurate as the difference between a technical error 
(sequencing or mapping induced) and a true variant will be more distinct and the 
reference bias introduced by mapping will decrease [47]. Both mapping and de 
novo assembly based variant detection will be highly reliable for simple forms of 
genetic variation such as single nucleotide variants (SNVs). More complex genetic 
events will, however, remain more challenging [40,48]. The detection and phasing 
of small (1-1000 bp) InDel events is still being improved [49], while comprehensive 
SVs is under constant development [48,50].
Per base sequencing costs and error rates will continue to drop and sequence 
read lengths increase [37,46]. Decreased costs will enable researchers to combine 
different approaches and technologies, for example short and long insert size 
libraries, to obtain a more accurate and complete assessment of an individual’s 
genetic variation [51]. The combination of approaches will allow the detection of 
different types of variants simultaneously and provide valuable data for accurate 
effect predictions. When sequencing reaches error rates below one error per 
million bases, and read lengths of several kbs, de novo assembly will be feasible and 
become a realistic alternative to mapping onto the reference genome. 
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Switching to de novo assembly computational time will increase only slightly due the 
availability of long unique reads, which can span repeat regions and easily merge 
scaffolds. Additionally long reads can directly provide allelic (phasing) information, 
which enables more accurate variant detection and interpretation. The greatest 
advantage of de novo assembly-based methods is that read mapping becomes 
independent of the human reference genome, which enables the reconstruction of 
rare genetic architectures, which can be population or even patient specific. While 
genome reconstruction by de novo assembly has already seen great improvements 
[52,53], there will be future challenges for bioinformatics to perform comprehensive 
variant identification.
Despite the advantages of assembly-based methods, these still rely on a reference 
or control genome for variant identification, as do reference mapping based 
methods. The dependency on a reference means that variant identification, and 
thereby genetic testing, will only be as reliable and complete as the reference 
genome(s). The current reference genome does not account for many complex 
forms or variability, such as inversion haplotypes or repeat expansions, present in 
the human genome [54]. Efforts to improve the reference genome will continue to 
have an impact on genetic testing results. I expect that more accurate sequencing 
and mapping combined with ongoing improvements of the human reference 
genome, through both computational and technical methods, will result in 99% 
of an individual’s genome to be routinely and affordably accessible for sequence 
comparison within five years.
Thus far, I have considered experiments that sequence DNA derived from a population 
of cells, such as whole blood. It is, however, known that genetic mosaicism occurs 
frequently in humans and have great impact on a person’s phenotype [55-57]. These 
forms of genetic variation are more difficult to detect than germline variants due to 
the signal intensity being determined by the level of mosaicism. Researchers need 
to test different tissues with high sensitivity to obtain an understanding of when and 
where the variant occurred [55,58]. New techniques such as single cell sequencing 
will be instrumental to obtain tissue and cell specific overviews of genetic variation 
[59]. A recent study using single cell data showed that mosaic CNVs of one Mb or 
larger affect 13-41% of neuronal cells in a healthy individual, indicating that the 
effects of mosaicism are especially relevant for human brain development [60].
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INTERPRETATION OF GENETIC VARIATION; THE NEXT CHALLENGE FOR 
BIOINFORMATICS IN GENETICS
It may be expected that sequencing and variant identification will become trivial 
in the next few years. Once an unambiguous assessment of the genetic variation 
in an individual’s genome can be obtained with a single test, interpretation of 
variants to explain or predict a (patient’s) phenotype will be the foremost remaining 
challenge. For bioinformatics, this constitutes a shift of focus from identification 
to interpretation, involving increasingly complex models to capture the underlying 
biology. The expected exponential increase in genetic data will also result in a 
greater demand for data storage, data transfer and standardization of data formats 
to enable research across and between datasets worldwide.
It will be most practical to start with predicting the effect of every single variant 
in relation to the patient’s phenotype. Once the effect of single variants can be 
predicted reliably scientists can combine predictions for variants in sets of genes, 
for example in a particular pathway. These intermediate steps will eventually enable 
the field to face the challenge of predicting the total effect of all genetic variation in 
an individual’s genome [26,61]. There are eight crucial parts in accurately predicting 
the phenotypic effect of an individual’s genetic variation in which bioinformatics 
will play an important role:
1. Inheritance: Allelic information for every variant
2. Population variation: Large amounts of phased control genomes
3. Phenotype data: Standardized and quantitative phenotypic data
4. Genome annotation: Accurate descriptions of the functional regions in the 
genome
5. Functional studies: Standardized and quantitative measurements
6. Prediction tools: More diverse and accurate variant effect prediction
7. Systems biology: Assessment of variant effect across different levels of biology
8. Combining predictions: Combined effect predictions across multiple variants
Figure 2 illustrates where the different parts (1-7) could play a role in the prediction 
of the phenotypic effect of a single variant. For the remainder of this chapter, I will 
focus on the practical usages and needs of bioinformatics in variant interpretation, 
since these bear most directly on the work presented in this thesis.
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Figure 2. Conceptual flowchart of a single variant interpretation model. Arrows indicate 
decisions, yes to the left, no to the right. Dashed arrows indicated the flow for common 
variants.
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1.) ALLELIC INFORMATION ABOUT EVERY VARIANT
Inheritance information was crucial in this thesis as we tried to explain the sporadic 
occurrence of intellectual disability (ID) [chapter 1-5]. The knowledge of the 
parental origin or de novo occurrence of genetic variants is highly informative in the 
selection of potential pathogenic variants. Moreover, this information is of utmost 
importance for the clinic when counseling for recurrence risk as inherited variants 
will constitute higher recurrence risks compared to de novo variants. Additionally, 
inheritance and allelic information will be an important component for automated 
variant interpretation models. It is for example clear that two pathogenic variations 
in a single gene will have a stronger effect on the phenotype when present on 
different alleles instead of on only one allele.
Bioinformatics can provide allele specific information through the process of 
phasing, which provides an in silico prediction of the allelic origin. Phasing is 
starting to be included in variant detection algorithms [36,49], and is more reliable 
and comprehensive for whole genome data compared to the fragmented data 
produced by WES and other targeted MPS approaches [62].
The addition of inheritance information to individual and population-based 
genotype databases will greatly improve their genotyping accuracy and 
usefulness in interpretation models. Bioinformatic variant calling algorithms can 
use allelic information to achieve more reliable and complete genotyping of a 
sample. Inheritance information for large numbers of individuals will also enable 
bioinformatics to construct models that are more accurate in the assessment of 
tolerance for genetic variation (mutational load) by enabling the assessment of 
individual alleles.
2.) LARGE AMOUNTS OF PHASED CONTROL GENOMES
Sequencing healthy individuals will be of great value in variant effect prediction; data 
on many individuals for a certain position provides a better understanding of the 
tolerated biological variation at that site. As more and more individual genomes are 
sequenced, more detailed maps of population structures and their corresponding 
variant frequencies can be generated. Efforts such as the 1000 genomes project 
[63], and the Genome of the Netherlands [64] are examples of efforts to establish 
more accurate datasets cataloguing genome-wide genetic variation. Correcting for 
factors such as ethnicity and population architecture will be essential for accurate 
variant effect prediction in a given individual [65].
The effectiveness of control genomes in interpretation is dependent on completeness 
of the information in the database. Important factors which influence a database’s 
utility are the level of validation of the variants, the level of detail of variant reporting 
(for example allelic information and ethnicity) and the size of the control dataset. 
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Information about the validation of a certain variant is crucial in interpretation 
models. A variant that has been validated (by an additional experiment) and does 
not have phenotypic effects in a functional assay will be far more informative 
compared to a variant identified in low coverage MPS data without additional 
follow-up. Current population frequency databases lack this information as well as 
inheritance information, limiting their use for variant interpretation.
Studies which provide a complete set of variants per individual, like the personal 
genome project [66], are of great value for interpretation of the effect of 
combinations of genetic variants, but they often lack allelic information. Variant co-
occurrence information can, for example, be incorporated into so-called mutational 
load models [67] (see prediction programs section).
Several hundred variants in an individual genome are rare in the general population 
and therefore a substantial number of control individuals are needed to interpret 
such rare variants based on frequency data. It is likely that a minimum of 10,000 
ethnically matched control genomes are needed to obtain an accurate assessment 
of variant frequencies and thereby allow deductions to be made on phenotypic 
effects. Ongoing projects for example in the UK and China aim to sequence 100,000 
and 1,000,000 control individuals respectively, to provide such accurate frequency 
estimates. Correct storage of these large datasets in a standardized format will be 
paramount for their utility in automated interpretation software. Initiatives like 
those from the Human Genome Variation Society [68] and the Global Alliance [69] 
try to raise awareness for these issues and engage large data centers to use open 
formats and facilitate open and efficient sharing of genetic and phenotypic data.
3.) STANDARDIZED AND QUANTITATIVE PHENOTYPIC DATA
In terms of availability and formats, phenotypic data has been relatively inaccessible 
to bioinformatics research. This is mostly because medical and/or phenotypic data 
is typically very unlike bioinformatics data (Figure 3). Medical data is often stored 
in non-digital formats, in the local language and usually based largely on subjective 
assessments rather than measurement based on objective classifications.
The value of standardized phenotypic information was demonstrated by the 
systematic phenotyping of knock-down/knock-out mice and the use of ontologies 
to systematically document phenotypic effects. This high level of standardization 
of these experiments has led to the successful implementation of mouse gene-
phenotype information in bioinformatic models and variant effect prediction 
algorithms [31,70,71]. Efforts to standardize phenotypic data from human 
individuals like the human phenotype ontology (HPO) [72] are essential to enable 
bioinformatics to study phenotypic similarities in humans in a standardized way and 
to incorporate human phenotypic data in prediction models [73].
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To date, most, if not all, existing databases storing phenotypic information lack the 
functionality to store quantitative measures. If a patient is for example described 
as macrocephalic, it is highly informative for computational models to know how 
many standard deviations this constitutes. The value of standardized quantitative 
phenotypic data in morphology related research has been previously shown 
[74]. That is, scientists performed 3D imaging on the faces of control individuals 
and individuals affected by different clinically recognized syndromes. Detailed 
quantitative data on facial characteristics such as nasal bridge width and eye 
spacing was used to determine and quantify differences between control and 
affected individuals [74,75]. This research illustrated the importance of recording 
and storing all phenotypes in a quantitative format: Studying the variability in the 
control groups allowed computer models to determine if patient phenotypes were 
significantly different from the control set and by what order of magnitude [74,75]. 
This method of assessing phenotypic information is less subjective than relying on 
the personal interpretation of a clinician.
Bioinformatics will have to play an important role in enabling clinicians to 
systematically store and share their phenotypic findings in a safe and easy way. 
There will need to be projects that develop intuitive user interfaces, in which 
clinicians can indicate which measurements have been performed, and compute 
(or indicate) the level of deviation from control individuals. Once readily available to 
each clinican/department, technologies like 3D imaging [74] will further reduce the 
Figure 3. Typical differences between bioinformatic and medical data. Schematic overview 
of the characteristics of bioinformatic (left) and medical (right) data
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number of individual measurements a clinician needs to perform while providing a 
rich data set for bioinformatics algorithms and models.
To promote the use and reporting of quantitative phenotypic measurements it 
will be important that scientific publications are enforced to provide numeric 
measurements of the relevant phenotypes of both control and affected individuals. 
Once phenotypes are routinely stored in appropriate databases, it will be essential 
to link genetic variants with a relation to the phenotype to these databases.
4.) ACCURATE DESCRIPTIONS OF THE FUNCTIONAL REGIONS IN THE GENOME
Genome annotation involves the systematic description and linking of biological 
functions to regions or a genomic location. The first genome annotation was 
cytobanding, staining patterns enabled scientists to identify and sort chromosome 
pairs. At present the human genome is annotated for over 21.000 genes and 
increasingly complex features such as measures of evolution, transcription factor 
binding sites, and methylation patterns [76]. Genome annotations will continue to 
become richer, current functions will be defined more accurately and the function 
of more regions, especially non-genic regions, will be elucidated. For example, the 
ENCODE project has already made substantial progress in annotating the non-coding 
functional regions of the human genome [76]. These developments will result in 
large data sets, and as a consequence annotations will become a data source to 
reckon with. Bioinformatics will need to construct more efficient methods to store, 
version and distribute these if they are to be incorporated effectively into prediction 
models.
An important challenge in the interpretation of genetic variants will be to attribute 
appropriate weights to the different annotations/biological functions. That is, will 
variation in a region annotated to act as both a transcription factor binding site and 
a methylation site be more important for transcriptional activation or deactivation? 
Studies that evaluate the effect of variants in a systems-biology wide manner (DNA, 
RNA, protein, etc.) will provide biological read-outs used by bioinformaticians to 
construct appropriate weight matrices for different biological functions.
Annotations for evolutionary conservation [77,78] provide a numerical value 
representing how essential a particular piece of DNA or protein has been throughout 
evolution. These conservation values have been successfully incorporated into 
prediction algorithms to provide an estimate of variation tolerance [79,80]. Currently 
the most reliable and readily available conservation values are based on nucleotide 
conservation across species [77,78]. While this has proven an indicative measure 
for variant pathogenicity [chapter 2], it cannot always be calculated and has limited 
value for truncating variants and variants affecting naturally variable sites, such as 
“wobble bases”. Importantly, genetic plasticity has already been described to have 
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more far reaching effects than the wobble base effect, for example through RNA 
editing [81,82]. As we learn more about biological complexity, more of such caveats 
will be identified which will need to be incorporated in bioinformatics models. In 
addition, evolutionary conservation provides little value when studying the effect 
of variants in human or primate specific genes. Human-specific conservation values 
will become more accurate through large-scale sequencing of human control 
genomes, as these provide insights into human specific variability. Bioinformatics 
models can incorporate the amount of genetic variability seen in control genomes 
as a metric for variant tolerance of a certain gene or region. A recent publication 
for example demonstrated that ID associated genes are on average less tolerant for 
genetic variation in the general population compared to other genes [83].
5.) STANDARDIZED AND QUANTITATIVE FUNCTIONAL MEASUREMENTS
Bioinformatics has gained most from functional studies when these were 
performed systematically for a large set of genes in an organism like the knock-out 
studies performed in mice [31]. Ideally, variation at every position in the genome is 
evaluated for all types of functional consequences, and against all possible genetic 
backgrounds. This is, however, unattainable from both an economical and practical 
perspective, as the combinations are nearly endless. A more achievable aim is 
when researchers systematically evaluate (all) genetic variants in a predetermined 
set of functionally relevant regions and compare these to control specimens, as 
demonstrated recently for ID gene knock-out fly models [84].
Something which is often lacking in these knock-out studies is rescue experiments 
with human analogs which provides valuable information about relevance to the 
human phenotype [85]. While functional studies currently have little bioinformatic 
involvement at the experimental level, the correct interpretation and storage 
of the measurements already depends greatly upon bioinformatics [71,86,87]. 
Quantitative measures on variant effects require statistics to describe a variants 
effect in terms of strength and directionality. The involvement of bioinformatics in 
functional studies will increase as imaging techniques are used more often, as these 
require pattern recognition to identify and quantitate phenotypic effects. This was 
recently shown for a single gene GATAD2B [86] and more generally for a systematic 
screen of ID gene knock-outs [84].
Previous examples relate to knock-out models, however, mutations can also have 
antagonistic or synergistic effects which can also be studied in model organisms. A 
clinical example for which systematic functional studies of different variant types 
were successfully performed is Bardet-Biedl Syndrome [85]. For this disorder, 
researchers could use a relatively high throughput organism, the zebra fish, while 
still obtaining clinically relevant functional read-outs [85]. Using various functional 
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studies researchers were able to show that multiple variants within the same 
complex were required before a clinical phenotype became apparent. An additional 
observation was that single variants could result in sub-clinical phenotypes 
[85]. This study illustrates the importance of not only testing manually selected 
candidate variants for a phenotype but systematically testing all variants within a 
complex or pathway, as well as their combinations. Variant effect databases will 
need to correctly store and classify such combinatorial tests and their effects. 
Bioinformatics can then mine these databases and construct programs that learn 
from these functional studies and construct rules on which types of variants will 
likely influence each other.
6.) MORE DIVERSE AND ACCURATE VARIANT EFFECT PREDICTION
Bioinformatics played an instrumental role in the interpretation of variants detected 
by aCGH and MPS through a combination of prediction programs and annotations 
[25,31,33]. However, these successes were in a large part due to their applicability 
to a certain set of genes or a specific type of disorder, as shown in this thesis for 
sporadic ID [chapter 2 & 3].
Current protocols to predict the general effect size of any given non-synonymous 
single nucleotide variant still need to be improved immensely [88]. Improvements 
have been made by combining the outcomes of different prediction software tools, 
each relying on different (genomic/evolutionary) features [89]. There are, however, 
some fundamental flaws in these programs that reduce their usefulness and 
accuracy. The largest problems are that these programs are, i) unable to correctly 
analyze gain of function or dominant negative variants, ii) unable to predict the 
effect of non-coding variants, and iii) unable to predict the effect of different types of 
variation (SVs, synonymous SNVs, in-frame InDels, etc.). Bioinformatics will resolving 
several of these issues by constructing more sophisticated prediction models and 
combining data sources, like interaction networks and domain annotations with 
stability metrics as described below.
An important metric in current prediction tools is the effect a variant has on 
stability or functionality of the affected element. For variants in the coding region, 
this is, mostly predicted based on the putative effect on protein stability. Accurate 
measurements on the change in protein stability and function require accurate 
3D models of the natural state and function of the affected protein. For example 
the effect prediction of variants involved in Cantú syndrome, affecting ABCC9 
[90,91], can only be done correctly when taking into account the presence and flux 
of potassium through the ion channel. The correct modeling of the biochemical 
function of proteins will allow prediction tools to more accurately predict the effect 
on stability of a variant.
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Predicting variant effects outside the coding region is an enormous challenge 
at present. Factors such as local DNA structure or sequence motifs [92] will 
be relevant metrics to estimate variant effects. A sequence motif captures the 
characteristics of a certain functional unit through sequence comparisons [93], 
usually in an evolutionary or genome wide perspective. Sequence motifs can be 
used to compute the degree of disruption of the element and secondly to define 
similar regions in the human genome to measure their variation tolerance in control 
genomes. Such region or pattern based methods will also help to interpret other 
forms of genetic variation. Rather than looking at a single nucleotide, predictions 
can be based on entire genomic regions. To predict the effect of complex events 
like SVs a correct reconstruction of the patient’s genome is essential to perform 
such region based analysis. For example, prediction programs need information on 
whether duplication events are situated in tandem or distal to each other, in order 
to characterize the disrupted regions and newly introduced elements. Local de novo 
assembly is a particularly useful bioinformatics tool in resolving these issues and 
will be more powerful as longer sequence reads become available.
7.) ASSESSMENT OF VARIANT EFFECT ACROSS DIFFERENT LEVELS OF BIOLOGY
An individual’s phenotype is not just the sum of the effects of each variant 
individually; there is an intricate interplay between genes, proteins and their 
regulatory mechanisms. Accounting for the biological complexity of genetic 
regulation and interaction will be a major challenge in constructing accurate variant 
effect prediction models.
Figure 4 depicts an example of a network containing both proteins and metabolites. 
In this network there are several proteins which are known to play a role in ID when 
mutated (in red). Effect prediction models will need data on the flow of signals and 
metabolites through the pathway and a complete overview of the interactions and 
their directions. Once these data are available, modeling can be performed in such 
a network to estimate if perturbations of different proteins have similar effects 
on the network. For example, one would like to investigate if another protein can 
counteract the perturbation through regulatory loops. When networks are detailed 
enough to answer these questions personalized medicine will start to become 
possible, as has been shown by preliminary successes for certain drugs [94]. For 
instance, for Warfarin, an anticoagulant used to prevent thrombosis, relative simple 
statistics of genotype and dosage effect correlation can now be used to provide a 
personalized medication advise for this drug [94].
To predict drug and variant effects throughout the body and across the different 
levels of biology will require high quality interaction, expression and metabolic 
networks. The construction of interaction and correlation networks of genes/
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proteins across different cell types, and stages of development, will require both 
detailed studies, in a single organ, as well as more general genomic and proteomic 
approaches [95]. Genome wide experiments in different tissues from healthy adult 
individuals will provide the backbone for these networks in terms of connectivity 
and directionality [95,96].
When phenotypic predictions need to me made about germline variants, the 
developmental processes in which the affected gene/genomic region is involved 
will form an essential part of the effect prediction model. Developmental studies 
will require more sophisticated experiments to capture the changes through time, 
which will limit the amount of available data [97]. Nonetheless, developmental 
experiments will provide the insights needed to construct models on how networks 
and interactions adapt throughout development and provide the data to capture 
such biological complexity in computer models. Fundamental principles in 
bioinformatics such as network and graph theory [2,98,99] will be instrumental in 
the construction and use of these complex networks in variant effect prediction.
Figure 4, Glutamergic synapse pathway from KEGG [98]. Components highlighted in orange 
are genes/proteins known to be mutated in individuals with ID [100,101].
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8.) COMBINED EFFECT PREDICTIONS ACROSS MULTIPLE VARIANTS
When sufficient data is available about the quantitative effect of a variant and the 
disrupted mechanisms, the final, and likely the toughest, challenge for bioinformatics 
will be the combined interpretation of all variants. In this process, all predictions of 
individual variants will need to be combined and weighted correctly to predict the 
net effect of all variation on the phenotype. Any assumptions or approximations 
made in previous steps will propagate into this combinational step and can be 
influenced in such a way that the outcome differs by orders of magnitude from the 
actual effect. It will be key to;
1. quantify the disruptive effect on the system
2. understand and quantify the directionality of the flow within the system.
In Figure 2, part of the classification relates to risks and modifiers, variants that 
have a milder or environment dependent effect. It is hard to predict the effect of 
such a variant by itself; it requires knowledge on genetic background and possibly 
environmental factors. Quantitative read-outs of variant effects will help interpret 
these modifiers and to consider their load in the complete model.
The importance of correctly assessing the net effect and combining the variants in 
prediction models was demonstrated by case studies in Bardet-Biedl Syndrome [85]. 
Despite having an appropriate functional read-out of the variant effects, the sum 
of the effects of every single variant was not equal to the effect in the specimens 
harboring the variants [85]. These combinatorial analyses will not only require a lot 
of computational power but also many connections between different data sources 
[102].
OTHER CHALLENGES RELATED TO BIOINFORMATICS AND GENETICS
Apart from the obvious role of bioinformatics in improving variation interpretation 
there are several other, more general, issues related to genomic experiments which 
I have not yet discussed in this thesis while they are important topics in current 
(political) debates [69,102]. Firstly, an ever changing and very important topic in 
human related research is privacy [103]. It has been shown that privacy cannot be 
guaranteed for rich data (in terms of identifiable features) such as genomic profiles 
[104,105]. It is important to realize this caveat and adjust consent accordingly as 
has been suggested by the “Personal Genome Project” and others [66,102,103]. 
Informatics will play an important role in data security, and thereby privacy, through 
encryption and access rights. It should, however, be noted that for the years to come 
(bioinformatics) research will benefit most readily from data available through open 
consent coupled to proper anti-discrimination legislation [102].
A second opportunity for bioinformatics, is the need for interfaces that explain 
genetic testing results to counselors and patients. Bioinformatics will continue to 
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play an essential role in bringing concepts such as risk and chance on disease to the 
field of personalized medicine. Companies like 23andMe present examples of how 
disease risks can be made understandable to the general population through figures 
and statistics. I envision that there will be an increase in (bioinformatic) companies 
developing and offering interpretation of genetic variants in terms of health and 
disease, but also in related fields such as match making and pre-conception genetics.
CLOSING REMARKS AND A BRIEF OUTLOOK
There are several points which have been discussed which I think will be crucial 
to the success of bioinformatics in future genetic research. The first is a point 
raised by many others [2,6,69,102], the need for standards and databases for both 
variants and phenotypes. Without these bioinformatics will be severely limited 
in its potential to link data sources and make correct inferences about genotype-
phenotype correlations. The second important issue is the need to realize that 
there are very few variants that will have the exact same phenotypic outcome in 
different individuals. Factors like ethnicity, epigenetics, regulation, expression levels 
and interactions are all part of the final equation and these types of data need to 
be gathered, stored and shared soon. This brings me to the next point, the need to 
share; many labs have excellent data about a certain pathway or a set of genes, if 
this data is made freely available to others I am confident that the field will progress 
even quicker.
This discussion started with the assumption that sequencing and variant 
identification will become trivial. In light of recent developments and the promise 
of emerging techniques such as single cell and nanopore sequencing [37,59,106], I 
think this assumption will become reality within the next five years. The next step 
is interpretation, to achieve a completely systematic and accurate interpretation 
of genetic variation, prediction models will ideally encompass a computer model 
of the complete human body [26,107]. While this may not be reality within five 
years from now, we may be able to unravel the underlying biological pathways of 
many diseases and start targeted treatment trials [108,109]. For certain genes and 
pathways we will be able to accurately identify and compute the effects of variation 
and understand their roles in disease [110]. Moreover, for heterogeneous disorders, 
such as ID, we will have a better understanding of the underlying genetic defects 
and their corresponding (sub) phenotypes allowing for more fine-grained studies 
on the underlying biochemical mechanisms and potentially studies aiming at gene 
or pathway specific treatment options.
A question which remains is whether advances in informatics, genetics, data sharing 
and bioinformatics, combined with new technologies such as nanopore and single 
cell sequencing will enable a bedside genome analyzer [37,106]. Such a machine 
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will sequence and interpret an individual’s genome in real time for a low price; while 
I am confident that this will become a reality, I do not expect it to happen within 
the next five years. Nonetheless, bioinformatics will continue to play an important 
role in bringing all the technological advances in the ‘omics’ fields together and 
combine these into personalized medicine, by linking data sources and providing 
comprehensive interpretation of variant effects, and finally in presenting these to 
researchers, clinicians and patients in an understandable and meaningful way.
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SUMMARY 
In this thesis the detection and role of newly occurring (de novo) mutations are 
studied in relation to ID. ID is typically defined by an intelligence quotient (IQ) below 
70 and (severe) developmental delays in adaptive behavior, starting before the age 
of 18 years. The research was focused on sporadic cases, with no familial history 
for the disorder. It has long been thought that the sporadic nature of ID might be 
explained by the occurrence of de novo germline mutations, referring to errors that 
occur in the genetic material during the formation of the egg- or sperm cell. There 
was however no supporting evidence for this hypothesis due to technical limitations 
for the detection of these mutations.
The availability of new genetic techniques allowed researchers to study de novo 
mutations genome wide (Chapter 1). It has been shown that de novo mutations 
can play an important role in both rare and common disorders. The extent to which 
de novo mutations impact the occurrence of human disease has been shown to 
depend on both genetic factors (like target mutability and size) and other factors 
such as parental age. The interpretation of the phenotypic effect of de novo 
mutations remains challenging and requires combinations of deep phenotyping, 
statistical analysis, functional studies and recurrence testing in additional cohorts 
of patients with ID.
The work described in this thesis focused mainly on sequencing the protein coding 
regions (the exome) of the human genome. Exome sequencing of 10 ID patients 
and their unaffected parents revealed that small (one to several base pairs) de novo 
mutations were the probable cause of ID in 6 patients (Chapter 2). The mutations in 
these patients occurred in genes involved in brain development and were predicted 
to impact protein function. These data showed that exome sequencing combined 
with a family-based experimental setup is a reliable method for the detection of de 
novo mutations. 
As our initial study suggested implications for preventive and diagnostic strategies in 
ID, we further evaluated the diagnostic utility of exome sequencing in 100 patients 
with severe unexplained ID, and their parents (Chapter 3). These patients had all 
reached the end stage of routine diagnostic procedures. A likely genetic cause 
of ID was identified in 16% of the patients, mostly based on de novo mutations. 
Additionally, in 19 patients de novo mutations were identified in candidate ID genes. 
We therefore postulated that the total diagnostic yield of this technique could be 
as high as 35% in this group of patients, and therefore warrants its implementation 
in routine diagnostics.
Apart from evaluating the ability of exome sequencing to identify small coding 
mutations we also investigated its ability to detect larger mutations in the form of 
CNVs (Chapter 4). CNVs delete or duplicate regions in the genome, thereby altering 
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the number of copies of that particular piece of DNA. The occurrence of de novo 
CNVs currently explains 10-20% of ID cases and these mutations are routinely 
detected using genomic microarrays. Their detection from sequencing data would 
be a valuable asset. A selection of 10 patients with 12 known, ID-related CNVs was 
used to assess whether these CNVs could be detected from exome sequencing data. 
To this end, four prediction programs were evaluated of which one was able to 
identify 11 of the 12 CNVs. From these data, we predict that 88% of all diagnostically 
relevant de novo CNVs (containing at least 3 exons) would be detectable from exome 
sequencing data, further increasing the utility of this technique in ID diagnostics.
Finally the novel sequencing technique was used in a genome wide manner to detect 
de novo chromosomal aneuploidies (Chapter 5) in a prenatal setting. Prenatal testing 
of fetal DNA for aneuploidies occurs mostly through invasive procedures, which 
have an intrinsic risk of miscarriage. Using a non-invasive test would circumvent 
this risk. Blood of pregnant women was used to determine whether chromosomal 
aneuploidies of the fetus could be reliably detected using whole genome massive 
parallel sequencing. Using this technique we were able to reliably detect copy 
number changes of whole chromosomes, suggesting that this test can readily be 
implemented in a prenatal setting, especially for chromosomes 13, 18, 21. 
Based on the increased diagnostic yield and the potential to reduce of the number 
of genetic tests performed per patient exome sequencing has now been included in 
the routine diagnostic strategy of patients coming to our clinic. The implementation 
of non-invasive prenatal trisomy testing is also well underway in The Netherlands 
because of the advantages mentioned above. Collectively, these examples 
illustrate the added diagnostic value of next generation sequencing approaches 
s in comparison to older techniques. With costs of sequencing decreasing in 
combination with its other advantages, it may be anticipated that next generation 
sequencing approaches will become the first tier genetic test for many diagnostic 
applications. However, the clinical interpretation of mutations identified by such 
tests is complex and requires a lot of multidisciplinary research. 
Our current knowledge of the human genome remains limited as we only now 
start to understand the function of a small percentage of the genome, mostly 
how disruptions in protein-coding parts can lead to disease. To further improve 
predictions of (de novo) mutations (Chapter 6) requires a better understanding of the 
genome and its variation in healthy individuals. Mutation effect prediction models 
will benefit from the inclusion of (tissue-specific) protein- and expression data. Also, 
linking genetic variation to (clinical) phenotypes and other biological data will be 
greatly substantiated by recording phenotypes in a standardized and quantitative 
manner. This together will eventually lead to a prediction of the combined effect of 
all genetic variation in a single model rather that each mutation separately.
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In dit proefschrift is de detectie en de rol van nieuw ontstane (de novo) mutaties 
onderzocht in relatie tot het ontstaan van een verstandelijke beperking (VB). VB 
wordt getypeerd door een intelligentie quotiënt (IQ) onder de 70 en (ernstige) 
ontwikkelingsstoornissen in adaptief gedrag, voor het 18de levensjaar. Het 
onderzoek was gericht op sporadische gevallen, zonder familiaire voorgeschiedenis 
voor de aandoening. Er is lang gedacht dat het sporadisch voorkomen van VB 
verklaart kon worden door de novo mutaties; fouten die ontstaan in het genetische 
materiaal tijdens de vorming van de ei- of zaadcel. Er was echter geen bewijs voor 
deze hypothese door technische beperkingen voor de detectie van deze mutaties.
De beschikbaarheid van nieuwe genetische technieken stelde onderzoekers in staat 
om de novo mutaties genoomwijd te bestuderen (hst. 1). Er werd aangetoond dat 
de novo mutaties een belangrijke rol kunnen spelen in het ontstaan van zowel 
zeldzame als vaak voorkomende aandoeningen. De mate waarin de novo mutaties 
invloed hebben op het ontstaan van ziekte is afhankelijk van zowel genetische 
factoren (de grootte en stabiliteit van het doelwit) als andere factoren zoals de 
leeftijd van de ouders. De interpretatie van het fenotypische effect van de novo 
mutaties blijft uitdagend en vereist combinaties van diepe fenotypering, statistische 
analyses, functionele testen en herhalingstesten in andere VB patiënten.
Het in dit proefschrift beschreven onderzoek richtte zich vooral op het sequencen 
van de eiwit coderende gebieden (het exoom) van het menselijk genoom. Exoom 
sequencing van 10 VB patiënten en hun gezonde ouders toonde aan dat kleine (een 
tot enkele basenparen) de novo mutaties de waarschijnlijke oorzaak waren van VB 
in 6 patiënten (hst. 2). De mutaties vonden plaats in genen die betrokken zijn bij de 
ontwikkeling van de hersenen en werden voorspeld de eiwit functie te beïnvloeden. 
De gegevens toonden aan dat exoom sequencing in zowel de patiënt als de ouders 
een betrouwbare methode is voor de detectie van de novo mutaties.
Omdat de eerste studie implicaties toonde voor preventieve en diagnostische 
strategieën in VB, evalueerden we de diagnostische bruikbaarheid bij 100 patiënten 
met ernstige onverklaarbare VB en hun ouders (hst. 3). Deze patiënten hadden 
het eindstadium van routine diagnostische procedures bereikt. Een waarschijnlijke 
genetische oorzaak van VB werd geïdentificeerd in 16% van de patiënten, meestal 
gebaseerd op de novo mutaties. Bovendien werden in 19 patiënten de novo 
mutaties geïdentificeerd in kandidaat VB genen. We verwachtten daarom dat de 
totale diagnostisch opbrengst van deze techniek zo hoog als 35% kan zijn in deze 
groep patiënten, en rechtvaardigt de toepassing in routine diagnostiek.
Naast het vermogen van exoom sequencing om kleine coderende mutaties te 
identificeren onderzochten we ook het vermogen om grote veranderingen te 
detecteren in de vorm van CNVs (hst. 4). CNVs verwijderen of dupliceren regio’s 
in het genoom, waardoor het aantal exemplaren van dat stuk DNA veranderd. 
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Het optreden van de novo CNVs verklaart momenteel 10-20% van VB gevallen, 
en wordt gedetecteerd met behulp van genomische microarrays. CNV detectie 
uit sequencing data zou een waardevolle toevoeging zijn. Een selectie van 10 
patiënten met 12 bekende, VB gerelateerde, CNVs werd gebruikt om te beoordelen 
of CNVs konden worden gedetecteerd met exoom sequencing. Hiertoe werden 
vier programma’s getest waarvan eentje 11 van de 12 CNVs detecteerde. Uit deze 
gegevens voorspelden wij dat 88% van diagnostisch relevante de novo CNVs (die 3 
of meer exonen bevatten) door exoom sequencing gedetecteerd kan worden, een 
verdere verbetering van deze techniek voor VB diagnostiek.
Tenslotte werd de nieuwe sequencing techniek prenataal gebruikt om op een 
genoom wijde manier de novo chromosomale aneuploïdieën te detecteren (hst. 
5). Prenataal onderzoek van foetaal DNA voor aneuploïdieën gebeurt meestal met 
invasieve procedures, die een intrinsiek risico op een miskraam hebben. Het gebruik 
van een niet-invasieve test zou dit risico omzeilen. Bloed van zwangere vrouwen 
werd gebruikt om te bepalen of chromosomale aneuploïdieën van de foetus 
betrouwbaar konden worden gedetecteerd met behulp van genoom sequencing. 
Met deze techniek konden we betrouwbaar duplicaties van gehele chromosomen 
detecteren, wat suggereerde dat deze test geïmplementeerd kan worden in 
prenataal onderzoek, specifiek voor chromosomen 13, 18, 21.
Op basis van de verhoogde opbrengst en de mogelijkheid van het terugbrengen 
van het aantal genetische tests per patiënt is exoom sequencing opgenomen in de 
routine diagnostiek in onze kliniek. De implementatie van niet-invasieve prenatale 
testen is in volle gang in Nederland vanwege de eerder genoemde voordelen. 
Tezamen illustreren deze voorbeelden de toegevoegde waarde ten opzichte van 
oudere technieken. De afnemende kosten van sequencing in combinatie met de 
andere voordelen wekt de verwachting dat sequencing de standaard genetische test 
wordt voor alle genetische aandoeningen. De klinische interpretatie en rapportage 
van mutaties geïdentificeerd door een dergelijke test is complex en vereist multi-
disciplinaair onderzoek.
Onze huidige kennis van het menselijk genoom is nog zeer beperkt, we beginnen 
een klein percentage van het genoom te begrijpen, met name hoe verstoringen 
in eiwit coderende delen kunnen leiden tot ziekte. Voorspellen of een (de novo) 
mutatie schadelijk is (hst. 6) vereist een beter begrip van het genoom en de variatie 
in gezonde individuen. Mutatie effect voorspellingsmodellen zullen profiteren van 
het gebruiken van (weefsel specifieke) eiwit en expressie data. Ook het koppelen 
van genetische variatie aan (klinische) fenotypes en andere biologische gegevens 
zal sterk worden ondersteund door het  gestandaardiseerd en kwantitatief opslaan 
van fenotypes. Dit samen zal uiteindelijk leiden tot een voorspelling van het 
gecombineerde effect van alle genetische variatie in een enkel model in plaats van 
elke mutatie afzonderlijk.
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en films kijken, jullie die bij de NCMLs PhD retreat mij vertrouwde om een kroeg te 
vinden, jullie die er bij de Batavieren race, de 7 heuvelen loop en de triatlon waren, 
jullie die op congres mee uit gingen, allemaal bedankt! Zonder gezelligheid geen 
wetenschap voor mij.
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Filosofische gedachte vloeide rijkelijk tijdens  onze bijeenkomsten en anders had 
Iemand wel een slechte grap. De drive om te winnen was groot en het spel was 
Fantastisch, behalve als het van Persie was, maar daar kon hij ook niks aan doen. 
Amateurs dat waren we ooit, nu zijn we volleerd, dames (REMBD) deze is voor 
jullie, de volgende keer weer bij mij?
Tim, Tom, Tom2 en Lex, Luxemburg en Bilbao brengen nog altijd een glimlach op 
mijn gezicht. Ik ben benieuwd wat de bestemming dit jaar wordt, het wordt weer 
eens tijd.
En dan natuurlijk mijn familie, alle ooms, tantes, neven en nichten die ieder familie 
weekend weer geïnteresseerd waren in wat ik deed en geduldig naar mijn soms erg 
omslachtige uitleg luisterde. Bedankt voor jullie vragen en enthousiasme. 
Lieve grootouders jullie wil ik bedanken voor een fantastische jeugd en het 
opvoeden van mijn lieve ouders, Opa, jou dank ik in het bijzonder, de reden dat ik 
dit boek aan jou opdraag is omdat jij van iedereen vaak de beste vragen stelde, niet 
alleen over mijn onderzoek maar ook over wetenschap in het algemeen, iets wat 
mij heeft geleerd altijd vragen te durven stellen. 
Lieve Marjoke, Paul & Ninge, afgezien van het feit dat ook jullie altijd geïnteresseerd 
en lief zijn hebben jullie ervoor gezorgd dat Jeuske is wie ze is, en daar ben ik jullie 
eeuwig dankbaar voor.
Lief schattig zusje (sorry kon het niet laten), lieve Marlies, altijd druk met studeren, 
en niet zonder resultaat, ook jij mag straks zo’n leuk ‘boekje’ gaan schrijven, maar 
dat komt vast goed. Bedankt voor al die gezellige vakanties en af en toe een bed om 
in te slapen. 
Lieve Els en Sjaak, of jullie het nu willen of niet, jullie zijn grotendeels verantwoordelijk 
voor dit boek, door jullie ben ik wie ik ben. Dank voor jullie steun in al die jaren, ook 
toen het wat minder ging bleven jullie er in geloven dat ik het kon, bij deze bewijs ik 
graag dat jullie gelijk hadden. 
Einstein & Newton, jullie zijn altijd een inspiratie en warmte bron voor mij geweest, 
bedankt voor alle kopjes en gespreksstof.
147
Dan de laatste, mijn alles, mijn schat, Jeuske, zonder jou was ik nooit zo gelukkig 
geweest als dat ik ben, en dat is behoorlijk gelukkig. Dank je voor je begrip als ik 
weer eens laat was of naar het buitenland moest, bedankt voor je goede zorgen 
terwijl ik ziek was of het weer eens heel druk had. Bedankt voor het grootste geluk 
in de wereld, kleine Lerris, ons gezinnetje, heerlijk. 
